WO1991013889A1 - Immunosuppressive macrocyclic compounds - Google Patents

Immunosuppressive macrocyclic compounds

Info

Publication number
WO1991013889A1
WO1991013889A1 PCT/GB1991/000393 GB9100393W WO1991013889A1 WO 1991013889 A1 WO1991013889 A1 WO 1991013889A1 GB 9100393 W GB9100393 W GB 9100393W WO 1991013889 A1 WO1991013889 A1 WO 1991013889A1
Authority
WO
Grant status
Application
Patent type
Prior art keywords
represents
compound
oh
formula
allyl
Prior art date
Application number
PCT/GB1991/000393
Other languages
French (fr)
Inventor
David Keith Donald
Mark Furber
Martin Edward Cooper
Original Assignee
Fisons Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen

Abstract

There are provided compounds of formula (I), wherein R1 represents H, OH or alkoxy; R2 represents H; in addition, R?1 and R2¿ may together represent a second bond between the carbon atoms to which they are attached; R3 represents methyl, ethyl, propyl or allyl; R4 represents H, OH, alkyl, alkoxy, halogen, amino, S-alkyl, NHCHO or NHCO-alkyl; n represents 1 or 2; X represents O, (H, OH), (H, H) or =NH; and Y represents an optionally substituted cyclohexyl or substituted cyclopentyl group; with various provisos. The compounds are useful, inter alia, as immunosuppressive agents.

Description

IMMUNOSUPPRESSIVE MACROCYCLIC COMPOUNDS

This invention relates to immunosuppressive macrocyclic compounds, processes for their preparation, their use as e medicaments, and compositions containing them.

European Patent Application 184162 (to Fujisawa Pharmaceuticals Co Ltd) discloses a number of macrocyclic compounds isolated from microorganisms belonging to the Q genus Streotomvces. The macrolides are numbered FR-900506, FR-900520, FR-900523 and FR-900525, and the preparation of some of their derivatives is also described.

International Patent Applications Nos WO 89/05304 and PCT/GB90/01262 and European Patent Application No 413532 (to Fisons pic) , European Patent Application 353678 (to Fujisawa Pharmaceuticals Co Ltd) , European Patent Applications 349049, 349061, 358508 and 388153 (to Merck & Co Inc) and European Patent Application 356399 and Q International Patent Application WO 90/15805 (to Sandoz AG) also disclose a number of immunosuppressive macrocyclic compounds.

We have now found a new group of immunosuppressiv macrocyclic compounds which possess advantageous propertie over those disclosed previously.

According to the present invention, there is provided compound of formula I,

wherein

R1 represents H, OH or alkoxy; c R2 represents H; in addition, R1 and R2 may together represent a second bond between the carbon atoms to which they are attached;

R3 represents methyl, ethyl, propyl or allyl;

R4 represents H, OH, alkyl, alkoxy, halogen, amino, Q S-alkyl, NHCHO or NHCO-alkyl; n represents 1 or 2;

X represents O, (H,OH) , (H,H) or -*NH; and

Y represents a cyclic group of formula II,

in which R5 represents (H,H), (H,OH) , (H,methoxy) or 0; R6 represents H, (R)-OH, (S)-OH, alkoxy, amino, alkylamino, alkanoylamino, formyloxy or halogen; R7 represents H; and in addition R5 and R6 may together represent a second bond between the carbon atoms to which they are attached; or R6 and R7 may together represent a second bond between the carbon atoms to which they are attached; or a cyclic group of formula III,

in which R8 represents alkyl substituted by one or more groups selected from OH, alkoxy, =0, and C02H; or alkenyl optionally substituted by one or more groups selected from OH, =0, or C02H; provided that a) when n represents 1; R1 represents OH; R3 represents allyl; R4 represents OH; R5 represents

(H,methoxy) ; and R6 represents (R)-OH; then X does not represent 0; b) when n represents 2; i) R1 represents OH; R3 represents methyl, ethyl, allyl or propyl; R4 represents OH; R5 represents (H,methoxy) ; and R6 represents (R)-OH; then X does not represent 0; ii) when R1 and R2 together represent a second bond between the carbon atoms to which they are attached or each represent H; R3 represents allyl or propyl; R4 represents OH; R5 represents (H,methoxy) ; and R6 represents (R)-OH; then X does not represent O;

5 iii) when R1 represents OH, methoxy or together with R2 it represents a second bond between the carbon atoms to which they are attached; R3 represents allyl; R4 represents OH; R5 represents (H,methoxy) ; and R6 represents methoxy; then X does not represent 0;

J_ iv) when R1 represents H or OH; R3 represents allyl; R4 represents OH; R5 represents (H,methoxy) ; and R6 represents (R)-OH; then X does not represent (H,0H) ; v) when R1 represents H; R3 represents propyl; R4 represents OH; R5 represents (H,0H) ; and R6 represents

15 (R)-OH; then X does not represent 0; vi) when R1 represents OH; R3 represents ethyl; R4 represents OH; R5 represents (H,methoxy) ; and R6 represents (R)-OH; then X does not represent (H,0H) ; vii) when R1 and R2 together represent a second bond

2Q between the carbon atoms to which they are attached or each represent H; R3 represents ethyl; R4 represents OH; R5 represents (H,methoxy) ; and R6 represents (R)-OH; then X does not represent 0; viii) when R1 represents OH; R3 represents allyl; R4

25 represents OH; R5 represents (H,0H) or (H,methoxy) ; and R6 represents (R)-OH; then X does not represent (H,H) ; ix) when R1 represents OH; R3 represents ethyl; R4 represents OH; R5 represents (H,methoxy) ; and R6 represents (R)-OH; then X does not represent (H,H) ; x) when R1 represents OH; R3 represents methyl, ethyl or allyl; R4 represents OH; R5 represents (H,OH) ; and R6 represents (R)-OH; then X does not represent O; and 5 xi) when R1 represents OH; R3 represents allyl; R4 represents OH; R5 represents 0; and R6 represents (R)-OH; then X does not represent 0; and pharmaceutically acceptable derivatives thereof.

^0 Pharmaceutically acceptable derivatives which may b mentioned include esters, amides and salts of an carboxylic acid groups which may be present. The ester and amides preferably contain up to 6 carbon atoms. Salt include alkali metal and alkaline earth metal salts, fo

-c example sodium or calcium.

When any one of R1, R4, R5, R6, and R8 represen carbon-containing groups, we prefer those groups to contai up to 10 carbon atoms, more preferably up to 6 carbo

20 atoms.

Groups which R may represent include CHO and C02H.

Preferably, R1 represents H or OH. We prefer R4 t 25 represent H, OH, alkyl, halogen or amino. Desirably, R represents (H,OH) or (H,methoxy) . Preferably R represents H, (R)-OH or amino. We prefer R8 to represen an amide of a C02H group or alkyl substituted by alkoxy. Subgroups of compounds which may be mentioned include: compounds of formula I in which Y represents a cyclic group of formula III; compounds of formula I in which R4 represents alkoxy; compounds of formula I in which R4

_ represents amino, alkylamino, alkanoylamino, halogen and thioalkyl; compounds of formula I in which R4 represents H or alkyl; and compounds of formula I in which R6 represents H, (S)-OH or halogen or together with R5 represents a second bond between the carbon atoms to which

Q they are attached or together represent a pair of vicinal hydrogen atoms.

A preferred group of specific compounds which may be mentioned is: 5 17-allyl-l,14-dihydroxy-12-[2-(3-methoxycyclohexyl)-1- methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-ll,28- dioxa-4-azatricyclo[22.3.1.04'9]octacos-18-ene-2,3,10,16- tetraone;

17-allyl-l,14-dihydroxy-12-[2-(cyclopentyl-3-carboxylic acid orpholine amide)-1-methylvinyl]-23,25-dimethoxy- 13,19,21,27-tetramethyl-ll,28-dioxa-4-azatricyclo [22.3.1.04'9]octacos-18-ene-2,3,10,16-tetraone; 17-allyl-14-hydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-l- methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-ll,28- dioxa-4-azatricyclo[22.3.1.04'9]octacos-18-ene-2,3,10,16- tetraon ;

17-allyl-14-hydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-l- methylvinyl]-23,25-dimethoxy-l,13,19,21,27-pentamethyl- 11,28-dioxa-4-azatricyclo[22.3.1.04'9]octacos-18-ene- 2,3,10,16-tetraone;

17-allyl-l-amino-14-hydroxy-12-[2-(4-hydroxy-3-methoxycyclo hexyl)-1-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetra methyl-11,28-dioxa-4-azatricyclo[22.3.1.04'9]octacos-18- ene-2,3,10,16-tetraone;

17-allyl-l-fluoro-14-hydroxy-12-[2-(4-hydroxy-3-methoxycycl hexyl)-1-methylvinyl]-23,25-dimethoxy-13,19,21,27- tetramethyl-ll,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos- 18-ene-2,3,10,16-tetraone;

17-Allyl-l,14-dihydroxy-12-[2-(cyclopentyl-3-methanol(methyl ether) )-1-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetra methyl-11,28-dioxa-4-azatricyclo[22.3.1.04'9]octacos-18- ene-2,3,10,16-tetr one; and 17-Allyl-l,14-dihydroxy-12-[2-(4-amino-3-methoxycyclohexyl) 1-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl- ll,28-dioxa-4-azatricyclo[22.3.1.04'9]octacos-18-ene- 2,3,10,16-tetraone.

The compounds disclosed in the above-mentioned application may be used as starting materials for the production o compounds of the present invention. Alternatively, the may be prepared by total synthesis.

According to a further aspect of the invention, there i provided a process for the production of a compound o formula I as defined in claim 1, which comprises: (a) producing a compound of formula I in which R1 an R2 together represent a second carbon-carbon bond between the carbon atoms to which they are attached, by dehydration of a corresponding compound in which R1 represents OH and R2 represents H; (b) producing a compound of formula I in which R1 and R2 each represent hydrogen, by reduction of a corresponding compound in which R1 and R2 together represent a second carbon-carbon bond between the carbon atoms to which they are attached; (c) producing a compound of formula I in which X represents (H,OH), by reduction of a corresponding compound in which X represents 0;

(d) producing a compound of formula I in which X represents (H,H) , by reduction of a corresponding compound in which X represents 0;

(e) producing a compound of formula I in which X represents 0, by oxidation of a corresponding compound in which X represents (H,OH) ;

(f) producing a compound of formula I in which R4 represents alkoxy, by reaction of a corresponding compound in which R4 represents OH and X represents (H,0H) with an alkanol;

(g) producing a compound of formula I in which R4 represents halogen, by reaction of a corresponding compound in which R4 represents OH with a suitable halogenating agent;

(h) producing a compound of formula I in which R4 represents H or alkyl, by reaction of a corresponding compound in which R4 represents halogen with an organometallic reagent;

(i) producing a compound of formula I in which R4 represents amino, by reaction of a corresponding compound in which R4 represents halogen with ammonia;

(j) producing a compound of formula I in which X represents =NH, by reaction of a corresponding compound in which X represents 0 with ammonia; (k) producing a compound of formula I in which R4 Q represents S-alkyl, by reaction of a corresponding compound in which R4 represents halogen with an alkylthiol; (1) producing a compound of formula I in which R4 represents NHCHO, by reaction of a corresponding compound in which R4 represents amino with formic acid; 5 (m) producing a compound of formula I in which R4 represents NHCO-alkyl, by reaction of a corresponding compound in which R4 represents amino with an alkanoic anhydride; (n) producing a compound of formula I in which R6 _ represents (S)-OH, by elimination of a leaving group from a correpsonding compound in which R6 represents the leaving group;

(o) producing a compound of formula I in which R6 represents H and R5 represents 0, by elimination of a leaving group from a correpsonding compound in which R6 represents the leaving group;

(p) producing a compound of formula I in which R6 and R7 together represent a second bond between the carbon atoms to which they are attached, by elimination of a leaving group from a correpsonding compound in which R6 represents the leaving group;

(q) producing a compound of formula I in which Y represents a cyclic group of formula III and R8 represents CHO, by elimination of a leaving group from a correpsonding compound in which R6 represents the leaving group; (r) producing a compound of formula I in which R6 represents halogen, by reaction of a corresponding compound in which R6 represents a leaving group with halide ion; (s) producing a compound of formula I in which R5 and R6 together represent a second bond between the carbon atoms to which they are attached, by elimination of halogen and alkoxy from a corresponding compound in which R5 represents alkoxy and R6 represents halogen; (t) producing a compound of formula I in which R5 represents (H,H) and R6 represents H, by reduction of a corresponding compound in which R5 and R6 together represent a second bond between the carbon atoms to which they are attached;

(u) producing a compound of formula I in which R6 represents H, by the action of hydride on a corresponding compound in which R represents a leaving group; (v) producing a compound of formula I in which R6 represents amino, by reduction of a corresponding compound in which R6 represents azido; (w) producing a compound of formula I in which R6 represents alkylamino or alkanoylamino, by reaction of a corresponding compound in which R6 represents amino with a suitable alkylating or acylating reagent; (x) producing a compound of formula I in which R8 5 represents alkyl substituted by OH, by reduction of a corresponding compound in which R8 represents alkyl substituted by =0;

(y) producing a compound of formula I in which R8 includes a carboxylic acid group, by oxidation of a Q corresponding compound in which R8 includes an aldehyde group; and

(z) producing a compound of formula I in which R8 represents optionally substituted alkenyl, by a Wittig reaction between a corresponding compound in which R8

,- includes an aldehyde and an appropriate Wittig reagent.

In process (a) , the dehydration may be carried out in solvent which does not adversely affect the reaction (e toluene) , in the presence of a trace amount of acid (e 20 p-toluenesulphonic acid) , at a temperature of from 50 t lOO'C.

In processes (b) and (t) , the reduction may be carried ou catalytically using hydrogen. Suitable catalysts includ platinum catalysts (eg platinum black, platinum oxides) palladium catalysts (eg palladium oxides, palladium o charcoal) , nickel catalysts (eg nickel oxide, Rane Nickel) , and rhodium catalysts (eg rhodium on alumina) Suitable solvents are those which do not adversely affect the reaction, and include methanol, ethanol, ethyl acetate, dichloromethane and dimethylformamide. The reduction may be carried out at or around room temperature.

In process (c) , suitable reagents for the reduction include tri-nbutyltin hydride in a solvent which does not adversely affect the reaction (eg toluene) at a temperature of from 50 to lOO'C, sodium borohydride, zinc in acetic acid at or around room temperature, sodium triacetoxyborohydride in acetic acid, L-Selectride

(Registered Trade Mark) in tetrahydrofuran, or borane/-butylamine complex in a solvent such as methanol or ethanol.

In process (d) , the reduction may be achieved by the action of H2S, preferably in the presence of pyridine or an amine (for example morpholine) , in a solvent which does not adversely affect the reaction (for example dimethylformamide, pyridine or methanol) , at or around room temperature.

In process (e) , the oxidation may be carried out in the presence of a suitable oxidizing agent, such as cupric acetate. Suitable solvents include those which do not adversely affect the reaction, for example methanol. The reaction may be carried out up to the reflux temperature of the solvent. In process (f) , the reaction may be carried out in the presence of a suitable acid catalyst, for example montmorillonite K10. The solvent used may conveniently be the alkanol reagent, and the reaction may be carried out at or around room temperature.

In process (g) , suitable halogenating agents include diethylaminosulphur trifluoride and thionyl chloride. The halogenation is preferably carried out in a solvent which does not adversely affect the reaction, for example dichloro ethane, at or below room temperature, and preferably under an inert atmosphere.

In process (h) , suitable organometallic reagents include lithium dialkyl copper reagents, which may be prepared from a copper halide and an alkyl lithium reagent. R4 preferably represents Cl in the starting material. Suitable solvents include those which do not adversely affect the reaction, for example diethyl ether. The reaction is preferably carried out at reduced temperature.

In processes (i) and (j), suitable solvents include thos which do not adversely affect the reaction, for exampl diethyl ether. R4 preferably represents Cl in th starting material. The reaction may be carried out at o around room temperature. In process (k) , suitable solvents include those which do not adversely affect the reaction, for example tetrahydrofuran (THF) . R4 preferably represents Cl in the starting material. The reaction may be carried out at or around room temperature.

In process (1) , the solvent is conveniently formic acid. The reaction may be carried out at or around room temperature, and in the presence of acetic anhydride.

In process (m) , suitable solvents include those which do not adversely affect the reaction, for example methanol.

The reaction may be carried out at below room temperature.

In processes (n)-(q), suitable leaving groups include tosylate, mesylate and triflate

(trifluoromethylsulphonyloxy) , and the elimination is carried out in the presence of an acid catalyst, preferably silica. The leaving group may be introduced by reaction of a compound of formula I in which R6 represents (R)-OH with a suitable reagent, for example trifluoro ethanesulphonic acid anhydride.

In process (r) , suitable leaving groups include tosylate, g mesylate and triflate. Suitable sources of halide include tetra-nbutylammonium halides, for example tetra-nbutylammonium iodide. Suitable solvents include those which do not adversely affect the reaction, for example benzene. The reaction may be carried out at at or around room temperature.

In process (s) , the elimination is preferably carried out by the action of powdered zinc. The solvent is preferably acetic acid and the reaction may be carried out at or around room temperature.

In process (u) , suitable leaving groups include imidazol-l-yl(thiocabonyl)oxy, which may be introduced by reaction of a corresponding compound in which R6 represents OH with l,l'-thiocarbonyldiimidazole. Suitable sources of hydride include tributyltin hydride, and the reaction is preferably carried out in the presence of AIBN. Suitable solvents include those which do not adversely affect the reaction, for example benzene. The reaction may be carried out up to the reflux temperature of the solvent.

In process (v) , suitable reducing agents includ 1,3-propanedithiol. Suitable solvents include those whic do not adversely affect the reaction, for exampl methanol. The reaction is preferably carried out in th presence of triethyla ine, and may be carried out at o around room temperature. The azido compound may b produced by the action of azide ion on a correspondin compound in which R6 represents a leaving group, fo example triflate. In process (w) , suitable alkylating agents include methyl iodide, and suitable acylating agents include acyl halides, for example acetyl chloride. Suitable solvents include those which do not adversely affect the reaction, for example dichloromethane. The reaction may be carried out at or around room temperature.

In process (x) , suitable reducing agents include L-Selectride. Suitable solvents include those which do not adversely affect the reaction, for example THF. The reaction is preferably carried out below room temperature.

In process (y) , suitable oxidizing agents include sodium chlorite, preferably in the presence of 1-methylcyclohex-l-ene. Suitable solvents include those which do not adversely affect the reaction, for example -butanol. The reaction is preferably carried out at or around room temperature.

In process (z) , suitable Wittig reagents include

(carbomethoxymethylene)triphenylphosphorane. Suitable solvents include those which do not adversely affect the reaction, for example toluene. The reaction may be carried out at or around the reflux temperature of the solvent.

Conventional methods may then be used to produce the corresponding acid and amides from the product obtained with this preferred reagent. Where necessary, hydroxy groups in intermediate compounds may be protected using conventional protecting group chemistry [as described in "Protective Groups in Organic Chemistry", ed: J W F McOmie, Plenum Press (1973), and "Protective Groups in Organic Synthesis", T W Greene, Wiley-Interscience (1981)]. A particularly useful protecting group which may be mentioned is -butyldimethylsilyl.

Compounds in which R4 represents halogen and compounds in which R6 represents a leaving group are useful in the production of corresponding compounds of formula I.

The compounds of formula I may be isolated from their reaction mixtures using conventional techniques.

The compounds of formula I are useful because they possess pharmacological activity in animals; in particular they are useful because they possess immunosuppressive activity, eg in the tests set out in Tests A, B, C and D. Thus the compounds are indicated for use in the treatment or prevention of resistance to transplanted organs or tissues, such as kidney, heart, lung, bone marrow, skin, cornea, etc; and of autoimmune, inflammatory, proliferative and hyperproliterative diseases, and of cutaneous manifestations of immunologically-mediated diseases: for example rheumatoid arthritis, lupus erythematosus, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, type 1 diabetes, uveitis, nephrotic syndrome, psoriasis, atopical dermatitis, contact dermatitis and further eczematous dermatitides, seborrheic dermatitis. Lichen planus. Pemphigus, bullous Pemphigoid, Epidermolysis bullosa, urticaria, angioedemas, vasculitides, erythemas, cutaneous eosinophilias. Alopecia areata, eosinophilic fasciitis, atherosclerosis etc.

The compounds of the invention are also indicated more generally in the treatment of respiratory diseases, for example reversible obstructive airways disease.

Further, the compounds of the invention are indicated in the treatment of a disease selected from intestinal inflammations/allergies such as Coeliac disease, proctitis, eosinophilic gastroenteritis, mastocytosis, Crohn's disease and ulcerative colitis; and food related allergic diseases which have symptomatic manifestation remote from the gasto-intestinal tract, for example migraine, rhinitis and eczema.

The compounds of the invention are also indicated for use as antimicrobial agents, and thus may be used in the treatment of diseases caused by pathogenic microorganisms and the like.

We therefore provide the use of compounds of formula I as pharmaceuticals.

Further, we provide the use of a compound of formula I the manufacture of a medicament for use as immunosuppressive agent.

For the above-mentioned therapeutic uses the dosa administered will, of course, vary with the compou employed, the mode of administration, the treatment desir (eg topical, parenteral or oral) and the disease indicate However, in general, satisfactory results are obtained wh the compounds are administered at a daily dosage of fr 0.001 to 20mg per kg of animal body weight.

For man the indicated total daily dosage is in the range from O.Olmg to lOOOmg and preferably from 0.5mg to lOOm which may be administered, for example twice weekly, or divided doses from 1 to 6 times a day or in sustain release form. Thus unit dosage forms suitable f o administration, eg oesophageally, comprise from O.Olmg to

500mg, and preferably 0.5mg to lOO g of the compo preferably admixed with a solid or liquid pharmaceutical acceptable diluent, carrier or adjuvant.

5 According to our invention we also provide a pharmaceuti composition comprising preferably less than 80%, and m preferably less than 50% by weight, of a compound of form I in combination with a pharmaceutically accepta - 20 -

adjuvant, diluent or carrier. Examples of suitable adjuvants, diluents or carriers are: for tablets, capsules and dragees - microcrystalline cellulose, calcium phosphate, diatomaceous earth, a sugar such as lactose, dextrose or mannitol, talc, stearic acid, starch, sodium bicarbonate and/or gelatin; for suppositories - natural or hardened oils or waxes; and for inhalation compositions - coarse lactose. The compound of formula I preferably is in a form having a mass median diameter of from 0.01 to lOμ . The compositions may also contain suitable preserving, stabilising and wetting agents, solubilisers (eg a water-soluble cellulose polymer such as hydroxypropyl methylcellulose, or a water-soluble glycol such as propylene glycol) , sweetening and colouring agents and flavourings. The compositions may, if desired, be

formulated in sustained release form.

For the treatment of reversible obstructive airways disease, we prefer the compound of formula I to be administered by inhalation to the lung, especially in the form of a powder.

According to a further aspect of the invention, there is provided a method of effecting immunosuppression which comprises administering a therapeutically effective amount of a compound of formula I, as defined above, to a patient. The compounds of formula I have the advantage that they are less toxic, more efficacious, are longer acting, have a broader range of activity, are more potent, are more stable, produce fewer side effects, are more easily absorbed or have other useful pharmacological properties, than compounds previously used in the therapeutic fields mentioned above.

The compounds of formula I have a number of chiral centres and may exist in a variety of stereoisomers. The invention provides all optical and stereoisomers, as well as racemic mixtures. The isomers may be resolved or separated by conventional techniques.

However, the preferred stereochemistry of various chiral carbon atoms are shown in formula la,

wherein R1 to R4, X and n are as first defined above, and Y represents a cyclic group of formula Ila or Ilia,

in which R to R8 are as first defined above.

Test A

Mixed Lymphocyte Reaction (MLR) I The MLR test was performed in microtitre plates, with each well containing 5 x 105 C57BL/6 responder cells (H-2b) , 5 x 105 mitomycin C treated (25μg/ml mitomycin C at 37--C for 30 minutes and washed three times with RPMI 1640 medium) BALB/C stimulator cells (H-2 ) in 0.2ml RPMI 1640 medium supplemented with 10% fetal calf serum, 2mM sodium hydrogen carbonate, penicillin (50μg/ml) and streptomycin (50μg/ml) . The cells were incubated at 37"C in a humidified atmosphere of 5% carbon dioxide and 95% of air for 68 hours and pulsed with 3H-thymidine (0.5μCi) 4 hours before the cells were collected. The object compound of this invention was dissolved in ethanol and further diluted in RPMI 1640 medium and added to the cultures to give final concentrations of O.lμg/ml or less. Test B

Mixed Lvmphocvte Reaction (MLR) II

The MLR test was performed in 96-well microtitre plates with each well containing 3 x 105 cells from each of two responding donors in a final volume of 0.2ml RPMI 1640 medium supplemented with 10% human serum, L-glutamine and penicillin/streptomycin. The compound under test was dissolved at lomg/ml in ethanol and further diluted in RPMI 1640. The cells were incubated at 37°C in a humidified atmosphere at 5% carbon dioxide for 96 hours. 3H-thymidine (0.5μCi) was added for the final 24 hours of the incubation to provide a measure of proliferation. Test C Graft versus Host Assay (GVH)

Spleen cells from DA and DAxLewis Fl hybrid rats were o prepared at approximately 10° cells/ml. 0.1ml of these suspensions were injected into the rear footpads of DAxLewis Fl rats (left and right respectively) . Recipient animals are dosed with the compound under test, either orally or subcutaneously, on days 0-4. The assay is terminated on day 7 when the popliteal lymph nodes of the animals are removed and weighed. The increase in weight of the left node relative to the weight of the right is a measure of the GVH response. Test D

Inhibition of Interleukin-2 (IL-2) secretion The test was performed following the method of S Sawada et al, J Immunol (6), Vol 139, ppl797-1803, but using the Jurkat cell line.

The invention is illustrated, but in no way limited, by the following Examples. Example 1

17-Allyl-14-hydroxy-12-r2-(4-hydroxy-3-methoxycvclohexyl)-1- methylvinyl1-1.23.25-trimethoxy-13.19.21.27-tetramethyl- 11.28-dioxa-4-azatricyclor22.3.1.04'9]octacos-18-ene- 2.3.10.16-tetraone

(a) 17-Allyl-2.14-dihvdroxy-12-r2-(4-hydroxy-3-methoxy cyclohexyl)-l-methylvinyl'1-1,23,25-trimethoxγ-13.19.21.27- tetramethyl-ll.28-dioxa-4-azatricyclor22.3.1.0 '91octacos- 18-ene-3.10.16-trione 17-Allyl-l,2,14-trihydroxy-12-[2-(4-hydroxy-3-methoxy cyclohexyl)-1-methylvinyl]-23,25-dimethoxy-13,19,21,27- tetramethyl-ll,28-dioxa-4-azatricyclo[22.3.1.04'9]octacos- 18-ene-3,10,16-trione (the compound of Example 5, WO 89/05304) (200mg) was added to a suspension of montmorillonite K10 (500mg) in methanol (5ml) . After stirring for 4 days at room temperature a further portion of montmorillonite was added (500mg) and stirring was continued for a further 2 days. The reaction mixture was then filtered through celite and was concentrated to an oil Q in vacuo. Column chromatography on silica then gave the subtitle compound as an oil (42mg) . MS: 843 [M+Na]+; 904 [M+Rb]+

(b) 17-Allyl-14-hydroxy-12-r2-(4-hydroxy-3-methoxycvclo hexyl)-1-methylvinyl1-l.23.25-trimethoxy-13.19.21.27- _ tetramethyl-11.28-dioxa-4-azatricvclor22.3.1.04'9]octacos- 18-ene-2.3.10.16-tetraone

The compound of step (a) (40mg) was dissolved in methanol (3ml) and to this was added cupric acetate (lOOmg) . The resulting suspension was stirred and heated to reflux for 30 minutes. The reaction mixture was then cooled, filtered and evaporated in vacuo. Column chromatography on silica gave the title compound (30mg) as an oil. MS (FAB): 902.5 [M+Rb]+; 840.8 [M+Na]+; 818.8 [M+H]+; 800.8 [M+H]+; 786.8 [M+H-CH3OH]+

13C NMR S : 211.7 (C16) ; 197.6 (C2) ; 169.3 (CIO); 166.2 (C3); 139.1 (C29) ; 130.5 (C31) ; 123.4 (C18) ; 116.7 (C42) ; 102.4 (Cl) ; 102.4 (Cl) ; 50.6 (CI-OCH3) Example 2

17-Allyl-l-amino-14-hydroxy-12-f2-(4-hvdroxy-3-methoxycyclo hexyl)-l-methylvinyl]-23.25-dimethoxy-13.19.21.27-tetra methyl-11.28-dioxa-4-azatricycloT22.3.1.04 ' ]octacos-18- ene-2.3.10.16-tetraone and

17-Allyl-l.14-dihγdroxy-12-r2-(4-hvdroxy-3-methoxycvclo hexyl)-l-methylvinyl]-23.25-dimethoxy-2-imino-13.19.21.27- tetramethyl-ll.28-dioxa-4-azatricyclor22.3.1.04"• 9]octacos- 18-ene-3.10.16-trione (a) 17-Allyl-l-chloro-14-hvdroxy-12- 2-(4-hvdroxy-3-methoxy cvclohexyl)-l-methylvinyll-23.25-dimethoxy-13.19.21.27-tetra methyl-11,28-dioxa-4-azatricyclof22.3.1.04 ' 9]octacos-18- ene-2.3.10.16-tetraone

A solution of 17-allyl-l,14-dihydroxy-12-[2-(4-hydroxy-3- methoxycyclohexyl)-1-methylvinyl]-23,25-dimethoxy- 13,19,21,27-tetramethyl-ll,28-dioxa-4-azatricyclo [22.3.1.0 '9]octacos-18-ene-2,3,10,16-tetraone (FR-900506) (0.6g) in dry dichloromethane (15ml) was added dropwise over 5 minutes at room temperature under an atmosphere of nitrogen to a solution of thionyl chloride (544μl) and pyridine (1.33ml) in dry dichloromethane (15ml) . After stirring for 5 minutes at room temperature the reaction mixture was added slowly to vigorously stirred saturated aqueous sodium hydrogen carbonate solution (50ml) . After stirring for 5 minutes this mixture was extracted with diethyl ether (150ml) and the extract washed with dilute aqueous hydrochloric acid (IM, 50ml) , water and brine before being dried (MgS04) , filtered and evaporated in vacuo to give the subtitle compound as a foam (630mg) . MS: 908.4 [M+Rb]+; 906.4 [M+Rb]+; 870.7 [M-HCl+Rb]+; 844.9 [M+H]+ 13C NMR (CDC13) δ : 212.1 (C16) ; 189.3 (C2) ; 169.3 (CIO); 164.1 (C3); 140.4 (C19) ; 135.8 (C41) ; 132.3 (C29) ; 129.4 (C31) ; 122.6 (C18) ; 116.6 (C42); 108.9 (Cl) ; 84.3 (C34) ; 70.3 (C14) ; 48.2 (C20) ; 41.3 (C13) ; 9.8 (C39) (b) 17-Allyl-l-amino-14-hydroxy-12-f2-(4-hvdroxy-3-methoxy cyclohexyl)-1-methylvinyll-23.25-dimethoxy-13.19.21.27-tetra Q methyl-11.28-dioxa-4-azatricyclof22.3.1.0 f91octacos-18- ene-2.3.10.16-tetraone and

17-Allyl-1.14-dihvdroxy-12-r2-(4-hydroxy-3-methoxycyclo hexyl)-l-methylvinyll-23.25-dimethoxy-2-imino-13.19.21.27- _ tetramethyl-11.28-dioxa-4-azatricyclo■r22.3.1.04-'91octacos- 18-ene-3.10.16-trione

A crude sample of the compound of step (a) (405mg) was taken up in THF (tetrahydrofuran) (8ml) and to this was added concentrated aqueous ammonia solution (4ml) . After stirring for 20 minutes at room temperature the reaction mixture was diluted with water (20ml) and diethyl ether

(50ml) . The organic extract was then separated and washed 5 with brine before being dried (MgS04) , filtered and concentrated in vacuo to a foam. This was chromatographed on silica using HPLC eluting with 2% methanol in diethyl ether to give fraction A (190mg) and fraction B (98mg) .

Fraction A was further purified by chromatography on silica 0 using HPLC eluting with ethyl acetate to give the first title compound (92mg) as a foam.

MS: 887.5 [M+Rb]+; 803.7 [M+H]+ 13C NMR (CDC13) δ : 213 (C16) ; 198.2 (C2) ; 169.2 (CIO);

166.2 (C3) ; 139.4 (C19) ; 135.7 (C41) ; 132.6 (C29) ; 129.6 5 (C31) ; 122.2 (C18) ; 116.5 (C42); 88.6 (Cl) ; 84.2 (C34) ;

76.7 (C12); 75.5 (C23) ; 71.1 (C24) ; 70.2 (C14) ; 56.4 (C9) ;

52.7 (C17) ; 48.6 (C20) ; 43.0 (C15) ; 39.9 (C13) ; 38.9 (C5) ;

31.3 (C36) ; 30.7 (C37) ; 27.9 (C8) ; 26.1 (C21) ; 24.6 (C6) ;

21.3 (C7) ; 20.4 (C44) ; 14.2 (C30) ; 9.5 (C39) Q Fraction B was further purified by chromatography on silica using HPLC eluting with hexane/acetone [2:1] to give the second title compound (70mg) as a foam.

MS: 887.5 [M+Rb]+; 825.7 [M+Na]+; 803.7 [M+H]+;

785.7 [M+H-H20]+; 767.7 [M+H-2H20]+ 2513C NMR (CDCI3) δ: 214.4 (C16) ; 175.7 (C2) ; 169.9 (CIO); 168 (C3); 139.1 (C19) ; 134.7 (C41) ; 131.3 (C29) ;

128.2 (C31) ; 123.4 (C18) ; 116.7 (C42) ; 95.5 (Cl) ; 84.2 (C34); 75.2 (C23); 73.4 (C25) ; 71.5 (C24) ; 69.5 (C14) ; 52.9 (C17) ; 49.8 (C20) ; 44.9 (C15) ; 39.6 (C13) ; 39.3 (C5) ; 31.2 (C36) ; 30.8 (C37) ; 27.7 (C8) ; 26.2 (C21) ; 24.3 (C6) ; 21.0 (C44) ; 20.0 (C7);14.5 (C30) ; 10.2 (C39) Example 3 5 17-Allvl-l-(l-thiopropvl)-14-hvdroxv-12-r2-(4-hvdroxv-3- methoxycvclohexyl)-1-methylvinyl1-23.25-dimethoxy- 13.19.21.27-tetramethyl-ll.28-dioxa-4-azatricyclo r22♦3.1.04'91octacos-18-ene-2.3.10.16-tetraone A solution of the compound of Example 2(a) (lOOmg) and 0 propanethiol (0.1ml) in THF (2ml) and saturated aqueous sodium hydrogen carbonate solution (2ml) was stirred vigorously for 24 hours at room temperature. Water (10ml) was then added and the reaction mixture was extracted with diethyl ether (20ml) . The organic extract was then washed with brine before being dried (MgS04) , filtered and evaporated to an oil in vacuo. Chromatography on silica eluting with hexane/acetone [3:1] then gave the title compound (42mg) as a foam. MS: 946 [M+Rb]+; 885 [M+Na]+; 863 [M+H]+;

20787 [M+H-CH3(CH2)2SH]+;

769 [M+H-CH3(CH2)2SH-H20]+ 13C NMR (CDCI3) δ : 212.8 (C16) ; 191 (C2) ; 169.3 (CIO); 166.7 (C3); 140.8 (C19) ; 135.2 (C41) ; 131.3 (C29) ; 128.7 (C31) ; 122.3 (C18) ; 116.8 (C42) ; 89.6 (Cl) ; 84.1 (C34) 2573.9 (C25) ; 73.5 (C35) ; 70.2 (C14) ; 56.1 (C9) ; 51.6 (C17) 48.9 (C20) ; 44.9 (C15) ; 39.4 (C13) ; 38.9 (C5) ; 36.4 (C40)

33.3 (C26) ; 31.1 (C36) ; 30.7 (C37) ; 29.3 (C8) ; 28.1 (C21)

27.4 (SCH2); 24.4 (C6) ; 21.8 (SCH2CH2) ; 21.0 (C44) 14.3 (C30) ; 13.6 (S(CH2)2CH3) ; 10.2 (C39) Example 4

17-Allyl-l-(N-acetyl)amino-14-hydroxy-12-r2-(4-hydroxy-3- methoxycyclohexyl)-l-methylvinyll-23.25-dimethoxy- 5 13.19.21.27-tetramethyl-ll.28-dioxa-4-azatricyclo r22.3.1.04,,91octacos-18-ene-2.3.10.16-tetraone A sample of the first title compound of Example 2 (crude, lOOmg) was taken up in methanol (10ml) and acetic anhydride (0.6ml) was added. After being stored at 4°C for 3 days 0 further acetic anhydride (0.3ml) was added and the reaction mixture was stored at this temperature for a further 2 days. The reaction mixture was then poured into saturated aqueous sodium hydrogen carbonate solution (100ml) and this was then extracted with diethyl ether (100ml) . The 5 separated organic extract after washing with brine was dried (MgS04) , filtered and concentrated in vacuo to a foam. Chromatography on silica eluting with dichloromethane/acetone in an increasing acetone gradient then gave material which was further purified by 0 chromatography on silica eluting with ethyl acetate to give the title compound (37mg) as a foam.

MS: 929.1 [M+Rb]+; 867.9 [M+Na]+; 846 [M+H]+; 769.1 [M+H-H20-CH3C0NH2]+ 13C NMR (CDCI3) δ : 212 (C16) ; 190.2 (C2) ; 169.8 (CIO); 25169.4 (CH3CONH) ; 163.1 (C3) ; 140.2 (C19) ; 135.6 (C41) ; 132.2 (C29) ; 129.4 (C31) ; 122.2 (C18) ; 116.4 (C42); 87.8 (Cl) ; 84.2 (C34); 76.8 (C12) ; 76.3 (C23) ; 74.9 (C24) ; 70.4 (C14); 52.7 (C17) ; 51.2 (C9) ; 47.8 (C20) ; 45.1 (C15) ; 44.1 (C5 ) ; 41. 6 (C13 ) ; 31.3 (C36) ; 30. 6 (C37 ) ; 27 . 3 (C8 ) ; 26 . 0 (C21) ; 24 . 3 (C6) ; 22.9 (CH3CONH) ; 21.4 (C7 ) ; 18 . 3 (C44 ) ; 16. 9 (C47 ) ; 15. 5 (C43 ) ; 14 . 8 (C30) ; 9 . 5 (C39 )

Further elution then gave the Cl isomeric compound (46mg) . MS: 929.1 [M+Rb]+; 867.5 [M+Na]+; 845.6 [M+H]+; 827.6 [M+H-OH]+; 768.6 [M+H-H20-CH3CONH2]+ 13C NMR (CDCI3) <S: 210.4 (C16) ; 194.3 (C2) ; 169.4

(CIO); 169.0 (CH3CONH) ; 166.1 (C3) ; 137.8 (C19) ; 135.7 (C41) ; 131.7 (C29) ; 129.5 (C31) ; 123.7 (C18) ; 116.5 (C42) ;

89.7 (Cl) ; 84.2 (C34) ; 77.9 (C12) ; 76.0 (C24); 74.5 (C23) ;

69.8 (C14); 39.5 (C13) ; 28.2 (C21) ; 27.3 (C8) ; 25.2 (C6) ; 23.1 (CH3CONH) ; 21.5 (C7) ; 16.9 (C47) ; 13.2 (C30) ; 9.9 (C39) Example 5

17-Allyl-l-(N-formyl)amino-14-hydroxγ-12-r2-(4-hydroxy-3- methoxycvclohexyl)-l-methylvinyl]-23.25-dimethoxy- 13.19.21.27-tetramethyl-ll.28-dioxa-4-azatricyclo r22.3.1.04'91octacos-18-ene-2.3.10.16-tetraone a) 17-Allyl-14-tbutyldimethylsilyloxy-12-r2-(4-

-butyldimethylsilyloxy-3-methoxycvclohexyl)-1-methylvinyl1 -23.25-dimethoxy-l-hydroxy-13.19.21.27-tetramethyl-ll.28- dioxa-4-azatricvclof22.3.1.04'91octacos-18-ene-2.3.10.16- tetraone _ To a solution of FR-900506 (500mg, 0.622mmole) in dry dichloromethane (20ml) at room temperature under nitrogen was added 2,6-dimethylpyridine (0.4ml) and -butyl- dimethylsilyl triflate (362mg, 1.32mmole). After 30 minutes at room temperature further -butyldimethylsilyl triflate (362mg, 1.32mmole) was added and the reaction mixture was stirred for a further 30 minutes at room temperature. Dichloromethane (30ml) was then added and the reaction mixture was extracted with dilute aqueous hydrochloric acid (25ml) and brine (25ml) . The organic extract was dried (MgS04) , filtered and evaporated to an oil in vacuo. Purification by column chromatography on silica eluting with hexane/acetone [9:1] gave the title compound (606mg, 94%) as an oil. MS: 1055 [M+Na]+; 1117 [M+Rb]+ b) 17-Allyl-l-chloro-12-r2-(4-tbutyldimethylsilyloxy-3- methoxycyclohexyl)-1-methylvinyl]-14--butyldimethyl silyloxy-23.25-dimethoxy-13.19.21.27-tetramethyl-ll.28-dioxa -4-azatricyclof22.3.1.04'91octacos-18-ene-2.3.10.16- tetraone

A sample of the compound of step (a) (lg) in dry dichloromethane (10ml) was added dropwise over 5 minutes to a stirred solution of thionyl chloride (0.35ml) and pyridine (0.94ml) in dry dichloromethane (10ml) . After stirring for a further 5 minutes at room temperature the reaction mixture was poured into saturated aqueous sodium hydrogen carbonate solution (50ml) and this was extracted with diethyl ether (100ml The separated organic extract after washing with dilute aqueous hydrochloric acid (IM, 50ml) , water and brine was then dried (MgS04) , filtered and concentrated in vacuo to give the subtitle compound as a foam (lg) . c) 17-Allyl-l-amino-12-r2-(4--butyldimethylsilyloxy-3- methoxycyclohexyl)-1-methylvinyl]-14-tbutyldimethyl silyloxy-23.25-dimethoxy-13.19.21.27-tetramethyl-ll.28-dioxa -4-azatricyclof22.3.1♦04'9]octacos-18-ene-2.3.10.16- tetraone

A sample of the crude subtitle compound from step (b) (744mg) was dissolved in THF (10ml) and this was then added dropwise to concentrated aqueous ammonia solution (5ml) . The reaction mixture after being stirred vigorously for 15 0 minutes was diluted with water (25ml) and diethyl ether (50ml) . The diethyl ether extract was then separated and was washed with brine before being dried (MgS04) , filtered and concentrated in vacuo to a foam. Chromatography on silica eluting with hexane/ethyl acetate 5 [5:1] then gave the subtitle compound as a foam (250mg) . d) 17-Allvl-l-(N-formvl)amino-12-r2-(4--butyldimethyl silyloxy-3-methoxycvclohexyl)-1-methylvinyll-14- -butyldimethylsilyloxy-23.25-dimethoxy-13.19.21.27- tetramethyl-ll.28-dioxa-4-azatricyclor22.3.1.0 ' 91octacos-

2018-ene-2.3.10.16-tetraone

To a crude sample of the subtitle compound from step (c) (120mg) in formic acid (4ml) at room temperature was added acetic anhydride (0.2ml) . After stirring for 4 hours at room temperature the reaction was stored at 4'C for 16

2 hours before being poured into saturated aqueous sodium hydrogen carbonate solution (100ml) . After stirring this mixture for 20 minutes at room temperature it was extracted with diethyl ether (50ml) and this extract was then washed with brine before being dried (MgS04) , filtered and concentrated in vacuo to give the subtitle compound as an oil. e) 17-Allyl-l-(N-formyl)amino-14-hvdroxy-12-r2-(4-hydroxy-

5 3-methoxycvclohexvl)-l-methvlvinyl]-23.25-dimethoxv- 13.19.21.27-tetramethyl-ll.28-dioxa-4-azatricyclo r22.3.1.04''9]octacos-18-ene-2.3.10.16-tetraone A crude sample of the subtitle compound from step (d) (120mg) was taken up in ' methanol (3ml) and aqueous 0 hydrofluoric acid was added (0.2ml). After 2 hours at room temperature the reaction mixture was poured into saturated aqueous sodium hydrogen carbonate solution (20ml) and this was then extracted with diethyl ether (40ml) . The separated organic extract was then washed with brine before 5 being dried (MgS04) , filtered and concentrated in vacuo to a foam. Chromatography on silica eluting with hexane/acetone [2:1] then gave the title compound (30mg) as a foam. MS: 915.2 [M+Rb]+; 831.6 [M+H]+; 813.6 [M+H-H20]+;

20768.6 [M+H-H20-H2NCH0]+ 13C NMR (CDC13) <S: 214.6 (C16) ; 193.6 (C2) ; 169.2 (CIO); 166.1 (C3); 159.9 (NHCOH) ; 137.2 (C19) ; 135.3 (C41) ; 122.6 (C18) ; 116.5 (C42) ; 88.7 (Cl) ; 84 (C34) ; 77.9 (C12) ; 69.2 (C14) ; 56.2 (C9) ; 48.7 (C20) ; 43.6 (C15) ; 39.9 (C13);

2524.2 (C6) ; 20.8 (C44) ; 16.7 (C47) ; 14.7 (C43) ; 14.0 (C30) ; 11.1 (C39) Example 6 17-Allyl-l-fluoro-14-hvdroxy-12-r2-(4-hvdroxy-3-methoxycvclo hexyl)-1-methylvinyl]-23.25-dimethoxy-13.19.21.27- tetramethyl-11.28-dioxa-4-azatricvclof22.3.1.04'91octacos- 18-ene-2.3.10.16-tetraone

To a cold (0"C) solution of the subtitle compound of Example 5(a) (250mg) in dry dichloromethane (10ml) under nitrogen was added diethylaminosulphur trifluoride (lOOmg) . After stirring for 2 hours at O'C the reaction mixture was poured into saturated aqueous sodium hydrogen carbonate solution (30ml) and this was then extracted with diethyl ether (100ml) . The separated organic extract after washing with brine was dried (MgS04) , filtered and concentrated in vacuo to a foam (248mg) . This was then dissolved in acetonitrile (10ml) and 40% aqueous hydrofluoric acid (0.2ml) was added. After being stirred for two hours at room temperature the reaction mixture was poured into saturated aqueous sodium hydrogen carbonate solution (50ml) and this was then extracted with diethyl ether (100ml) . The separated organic extract was then washed with brine and was dried (MgS04) , filtered and concentrated in vacuo to an oil. Chromatography on silica eluting with dichloromethane/acetonitrile [2:1] then gave the title compound (28mg) as a foam.

MS: 890.5 [M+Rb]+; 828.9 [M+Na]+; 787 [M+H-HF]+; 769 [M+H-HF-H20]+

1?F NMR δ : -139.55 (d,J=28.15Hz) ; -141.55 (d,J=28.15Hz)

(two rotamers)

13C NMR (CDC13) δ : 211.9 (C16) ; 192.3 (C2) ; 169 (CIO); 164.2 (C3); 140 (C19) ; 135.6 (C41) ; 132 (C29) ; 129.5 (C31) ; 122.8 (C18) ; 116.5 (C42) ; 112.8 (Cl) ; 84.2 (C34) 77.2 (C12); 76.0 (C23); 75.1 (C25) ; 73.5 (C35) ; 72.5 (C24) 69.8 (C14) ; 48.1 (C20) ; 45 (C5) ; 43.8 (C15) ; 40.8 (C13) 32.3 (C26) ; 31.2 (C36) ; 30.7 (C37) ; 26.8 (C8) ; 25.9 (C21) 25.0 (C6) ; 21.7 (C7) ; 19.4 (C44) ; 15.8 (C47) ; 15.1 (C43) 14.5 (C30) ; 9.7 (C39) Example 7

The first title compound of Example 2 was tested in Test D, and found to inhibit IL-2 secretion by 50% (IC50) at a concentration of 2xlO~10M. Example 8 17-Allyl-1.14-dihydroxy-12-r2-(cyclopentyl-3-carboxaldehvde)

-1-methylvinyll-23.25-dimethoxy-13.19.21.27-tetramethyl- ll.28-dioxa-4-azatricyclof22.3.1.04'91octacos-18-ene- 2.3.10.16-tetraone

(a) 17-Allyl-l-hydroxy-12-r2-(4-hydroxy-3-methoxycyclo hexyl)-1-methylvinyl1-14--butyldimethylsilyloxy-23.25- dimethoxy-13.19.21.27-tetramethyl-ll.28-dioxa-4-azatricyclo r22.3.1.04 91octacos-18-ene-2.3.10.16-tetraone A solution of the product from Example 5(a) (1.28g) in methanol (100ml) containing pyridinium p-toluene sulphonate was stirred for 18 hours at room temperature. Volatiles were then removed in vacuo and the residue was dissolved in diethyl ether. The ethereal solution after washing with saturated aqueous sodium hydrogen carbonate solution, dilute aqueous hydrochloric acid (IN) , saturated aqueous sodium hydrogen carbonate solution and brine was dried (MgS04) , filtered and evaporated in vacuo to give the subtitle compound as a pale yellow foam (0.97g).

(b) 17-Allyl-l-hvdroxγ-12-r2-(4-trifluoromethylsulphonyloxγ -3-methoxycvclohexyl)-l-methylvinyll-14-~butyldimethyl silyloxy-23.25-dimethoxy-13.19.21.27-tetramethyl-ll.28-dioxa -4-azatricyclor22.3.1.04'9]octacos-18-ene-2.3.10.16- tetraone

To a cold (-10"C) stirred solution of the product of step (a) (0.97g) in dry dichloromethane (25ml) under nitrogen was added trifluoromethanesulphonic anhydride (0.1ml). After stirring for 15 minutes at -10"C, saturated aqueous sodium hydrogen carbonate solution was added and the reaction mixture was extracted with diethyl ether. The ether extracts were then washed with saturated aqueous sodium hydrogen carbonate solution, dilute aqueous hydrochloric acid (IN) , saturated aqueous sodium hydrogen carbonate solution and brine before being dried (MgS04) , filtered and concentrated in vacuo to give the title compound as an oil (0.95g).

(c) 17-Allyl-l-hvdroxy-12-r2-(cyclopentyl-3-carboxaldehvde) ~l~methylvinyl]-14--butyldimethylsilyloxy-23.25-dimethoxy-

13.19.21.27-tetramethyl-ll.28-dioxa-4-azatricyclo r22.3.1.0 '91octacos-18-ene-2.3.10.16-tetraone Silica (55g, Merck Kieselgel 60) was added to a solution of the product from step (b) (0.9g) in dichloromethane (250ml) . Volatiles were then removed in vacuo at room temperature and the resulting freely flowing powder was stored at 8*C for 16 hours. The support was then washed with ethyl acetate and 10% acetone in ethyl acetate containing 2,6-dimethylpyridine. The combined organic extracts after washing with, saturated aqueous sodium hydrogen carbonate solution, dilute aqueous hydrochloric acid (IN) , saturated aqueous sodium hydrogen carbonate solution and brine were dried (MgS04) , filtered and concentrated to an oil in vacuo. Chromatography on silica eluting with hexane in an acetone gradient then gave the title compound (0.126g) as a foam, (d) 17-Allyl-1.14-dihvdroxy-12-r2-(cvclopentyl-3- carboxaldehyde)-l-methylvinyll-23.25-dimethoxy-13.19.21.27- tetramethyl-ll.28-dioxa-4-azatricyclo[22.3.1.04'91octacos- 18-ene-2.3.10.16-tetraone

To a solution of the compound of step (c) (25mg) in acetonitrile (5ml) was added 40% aqueous hydrofluoric acid (1ml) • After stirring for 1 hour at room temperature the reaction mixture was poured into saturated aqueous sodium hydrogen carbonate solution and the mixture was extracted with diethyl ether. The organic extract was then dried, (MgS04) , filtered and evaporated to an oil in vacuo. Chromatography on silica eluting with acetone/hexane [1:2] then gave the title compound (18mg) as a foam. Example 9'

1.14-dihydroxy-12-r2-(cyclopentyl-3-carboxaldehyde)-1- methylvinyl1-23.25-dimethoxy-17-propyl-13.19.21.27- tetramethyl-11.28-dioxa-4-azatricyclof22.3.1.0 '91octacos- 18-ene-2.3.10.16-tetraone

To a solution of the product of Example 8 (15mg) in methanol (4ml) was added Pd-on-C (4mg, 10%) and the resulting suspension was then stirred in an atmosphere of hydrogen for 1 hour at 0βC. The reaction mixture was then filtered and volatiles were removed in vacuo. Chromatography on silica then gave the title compound as a foam (13mg) . Example 10

17-Allyl-l.14-dihydroxy-12- \ 2-(cvclopentyl-3-methanol)- 1-methylvinyl]-23.25-dimethoxy-13.19.21.27-tetramethyl- ll.28-dioxa-4-azatricvclor22.3.1.04'91octacos-18-ene- 2.3.10.16-tetraone

(a) 17-Allyl-l-hydroxy-12-r2-(cyclopentyl-3-methanol)-1- methylvinyll-14--butyldimethylsilyloxy-23.25-dimethoxy- 13.19.21.27-tetramethyl-ll.28-dioxa-4-azatricvclo r22.3.1.04,,91octacos-18-ene-2.3.10.16-tetraone To a solution of the product of Example 8(c) (170mg) in dry THF (15ml) at -70βC was added a solution of L-selectride in THF (IM) slowly under nitrogen until no starting material remained (0.4ml). Saturated aqueous ammonium chloride solution (0.5ml) was then added at -70βC followed by aqueous hydrogen peroxide solution (30% by weight, 1ml) and ethanolamine (0.1ml). After warming to 0°C the reaction mixture was extracted with diethyl ether and this was washed with water (x2) , dilute aqueous hydrochloric acid (IN) and saturated aqueous sodium hydrogen carbonate solution, before being dried (MgS04) , filtered and evaporated to an oil in vacuo. Chromatography on silica eluting with acetone/hexane [2:7] then gave the title compound (151mg) as a foam. S (FAB): 911 [M+Na]+; 972 [M+Rb]+.

(b) 17-Allyl-1.14-dihvdroxy-12-r2-(cvclopentyl-3-methanol)- 1-methylvinyl1-23.25-dimethoxy-13.19.21.27-tetramethyl- ll.28-dioxa-4-azatricvclor22.3.1.04-t-^1octacos-18-ene- 2.3.10.16-tetraone

To a solution of the product of step (a) (150mg) in acetonitrile (20ml) was added 40% aqueous hydrofluoric acid (3ml) . After stirring for 1 hour at room temperature the reaction mixture was poured into saturated aqueous sodium hydrogen carbonate solution and the mixture was extracted with diethyl ether. The organic extracts were then dried, (MgS04) , filtered and evaporated to an oil in vacuo. Chromatography on silica eluting with acetone/hexane [1:3] then gave the title compound (130mg) as a foam. MS (plasma spray): 738.54 [M+H-2H20]+; 756.58 [M+H-H20]+; 774.6 [M+H]+; 791.57 [M+NH4]+

13C NMR (CDC13) δ : (Major rotamer) 212.5 (C16) 196.2 (C2) ; 169 (CIO); 164.7 (C3) ; 138.8 (C19) ; 135.5 (C40) ; 131.4 (C31) ; 131 (C29) ; 122.4 (C18) ; 116.5 (C41) ; 97 (Cl) ; 77.7 (C12); 75 (C23) ; 69.9 (C14) ; 67 (C37) ; 56.5 (C9) ; 48.5 (C20) ; 43.6 (C15) ; 27.6 (C8) ; 26 (C21) ; 24.4 (C6) ; 20.9 (C7) ; 20.3 (C43); 13.9 (C30) ; 9.5 (C38) Example 11 1.14-dihvdroxy-12-r2-(cyclopentyl-3-methanol)-l-methylvinyl1 -23.25-dimethoxy-17-propyl-13.19.21.27-tetramethyl-ll.28- dioxa-4-azatricyclor22.3.1.04'9]octacos-18-ene-2.3.10.16- tetraone To a solution of the title compound of Example 10 (22mg) i methanol (10ml) was added 10% Pd-on-C (5mg) and the resulting suspension was then stirred in an atmosphere of hydrogen for 2 hours at 0βC. The reaction mixture was then filtered and volatiles were removed in vacuo. Chromatography on silica then gave the title compound as a foam (18mg) .

MS (plasma spray): 794 [M+NH4]+ Example 12 17-Allyl-l-hvdroxy-12-r2-(cyclopentyl-3-carboxylic acid) -l-methylvinyll-14- butyldimethylsilyloxy-23.25-dimethoxy- 13.19.21.27-tetramethyl-ll.28-dioxa-4-azatricyclo [22♦3.1.0 '91octacos-18-ene-2.3.10.16-tetraone To a solution of the product of Example 8(c) (393mg) in -butanol (30ml) containing 1-methylcyclohex-l-ene (4ml) was added dropwise a solution of sodium chlorite (0.75g) and sodium phosphate (0.75g) in distilled water (10ml) . After stirring for 10 minutes at room temperature the reaction mixture was partitioned between ethyl acetate and water and the organic extract was separated. This was then washed with aqueous sodium phosphate solution, an aqueous sodium thiosulphate/sodium phosphate mixture and aqueous sodium phosphate solution before being dried (MgS04) , filtered and evaporated in vacuo to give the title compound (350mg) as a foam. Example 13

17-Allyl-l.14-dihydroxy-12-f2-(cvclopentyl-3-carboxylic acid)-1-methylvinyl1-23.25-dimethoxy-13.19.21.27- tetramethyl-ll.28-dioxa-4-azatricyclor22.3.1.04--9-]octacos- 18-ene-2.3.10.16-tetraone

To a solution of the product of Example 12 (350mg) in acetonitrile (30ml) was added 40% aqueous hydrofluoric acid

(3ml) . After stirring for 1.5 hours at room temperature the reaction mixture was poured into ethyl acetate and the organic extract was washed with water and saturated aqueous sodium phosphate solution (x4) before being dried

(MgS04) , filtered and evaporated to an oil in vacuo.

Chromatography on silica eluting with acetone/hexane/acetic acid [40:10:1] then gave the title compound (32mg) as a foam.

MS (FAB): 771.02 [M-0H+H]+; 811 [M+Na]+; 872.72

[M+Rb]+ 13C NMR δ : (Major rotamer) 212.6 (C16) ; 196.1 (C2) 181.6 (C37) ; 169.1 (CIO); 164.7 (C3) ; 138.9 (C19) ; 135.6

(C40) ; 132.7 (C29) ; 130.3 (C31) ; 122.6 (C18) ; 116.7 (C41) ;

98.6 (Cl) ; 77.8 (C12) ; 75.3 (C23) ; 73.6 (C25) ; 72.6 (C24), '

70.0 (C14) ; 56.7 (C9) ; 52.9 (C17) ; 48.7 (C20) ; 26.3 (C21) ;

24.6 (C6) ; 21.1 (C7) ; 20.4 (C43) ; 14.1 (C30) ; 9.7 (C38) . Exam le 1

17-Allyl-1.14-dihydroxy-12-r2-(cyclopentyl-3-carboxylic acid methyl ester)-1-methylvinyl]-23.25-dimethoxy-

13.19.21.27-tetramethyl-ll.28-dioxa-4-azatricyclo

T22.3.1.04--9-]octacos-18-ene-2.3.10.16-tetraone _ To a solution of the product of Example 13 (25mg) i diethyl ether (5ml) at 0'C was added diazomethane.

Volatiles were then removed in vacuo to give the titl compound as a foam (25mg) . Example 15

1.14-dihydroxy-12-r2-(cvclopentγl-3-carboxylic acid methyl ester)-1-methylvinyl]-23.25-dimethoxy-17-propyl-13.19.21.27- tetramethyl-11.28-dioxa-4-azatricvclor22.3.1.04---9-1octacos- 18-ene-2.3.10.16-tetraone

To a solution of the product of Example 14 (20mg) in methanol (10ml) was added 10% Pd-on-C (4mg) and the resulting suspension was then stirred in an atmosphere of hydrogen for 2 hours at 0'C. The reaction mixture was then filtered and volatiles were removed in vacuo. Chromatography on silica then gave the title compound as a foam (17mg) . Example 16 1.14-dihvdroxy-12-r2-(cvclopentγl-3-carboxylic acid) -1-methylvinyl1-23.25-dimethoxy-17-propyl-13.19.21.27- tetramethyl-ll.28-dioxa-4-azatricyclor22.3.1.0---9-1octacos- 18-ene-2.3.10.16-tetraone

To a solution of the product of Example 15 (18mg) in methanol (10ml) was added 10% Pd-on-C (4mg) and the resulting suspension was then stirred in an atmosphere of hydrogen for 2 hours at 0QC. The reaction mixture was then filtered and volatiles were removed in vacuo. Chromatography on silica then gave the title compound as a foam (17mg) . MS (FAB): 874 [M+Rb]+ Example 17

17-Allyl-l-hvdroxy-12-r2-(cvclopentyl-3-methyl prooenoate)-1-methylvinyll-14- butyldimethylsilyloxy- 23.25-dimethoxy-13.19.21.27-tetramethyl-ll.28-dioxa-4- azatricvclor22.3.1.04 91octacos-18-ene-2.3.10.16-tetraone A solution of the product of Example 8(d) (140mg) and (carbomethoxymethylene)triphenylphosphorane (140mg) in dry distilled toluene (10ml) was stirred and heated at 70βC for one hour. After stirring at room temperature overnight the reaction mixture was diluted with diethyl ether and this was then washed with saturated aqueous sodium hydrogen carbonate solution and brine. The organic extract was then dried (MgS04) , filtered and evaporated to an oil in vacuo. Chromatography on silica eluting with hexane in an increasing diethyl ether gradient then gave the title compound (70mg) as a foam. Example 18 17-Allyl-1.14-dihydroxy-12-r2-(cyclopentyl-3-methyl propenoate)-1-methylvinyll-23.25-dimethoxy-13.19.21.27- tetramethyl-ll.28-dioxa-4-azatricvclor22.3.1.0 '91 octacos-18-ene-2.3.10.16-tetraone To a solution of the product of Example 17 (70mg) in Q acetonitrile (10ml) was added 40% aqueous hydrofluoric acid (lml) . After stirring for 1 hour at room temperature the reaction mixture was poured into saturated aqueous sodium hydrogen carbonate solution and the mixture was extracted with diethyl ether. The combined ether extracts, after 5 washing with saturated aqueous sodium hydrogen carbonate solution, were dried (MgS04) , filtered and concentrated to an oil in vacuo. Chromatography on silica eluting with hexane in an increasing acetone gradient then gave the title compound (55mg) as a foam.

MS (plasma spray): 792.78 [M+H-2H20]+; 810.80 [M+H-H20]+; 828.86 [M+H]+; 845.84 [M+NH4]+ MS (negative plasma spray): 826.09 [M-H]+ 5 -H NMR (CDC13) δ : 6.93 (1H, dd, J=8.1 and 16.6 Hz); 5.78 (1H, d, J=5.78 Hz), 3.71 (3H, S, C02Me)

13C NMR δ : (Major rotamer) 212.4 (C16) ; 196.1 (C2) ; 153.3 (C38); 138.8 (C19) ; 135.4 (C43) ; 122.6 (C18) ; 119 (C37) ; 116.6 (C44) ; 97.1 (Cl) ; 56.6 (C9) ; 51.3 (C40) ; 9.7 0 (C41).

Example 19

1.14-dihvdroxγ-12-[2-(cyclopentyl-3-carboxaldehyde)-l-methyl vinyl]-23.25-dimethoxy-17-ethyl-13.19.21.27-tetramethyl- ll.28-dioxa-4-azatricvclof22.3.1.0 >*91octacos-18-ene- 5 2.3.10.16-tetraone

(a) l-Hydroxγ-12-[2-(cγclopentyl-3-carboxaldehyde)-l-methyl vinvll-14-tbutvldimethvlsilvloxv-23.25-dimethoxv-17-ethvl- 13.19.21.27-tetramethyl-ll.28-dioxa-4-azatricvclo ι~22.3.1.04'91octacos-18-ene-2.3.10.16-tetraone 0 The subtitle compound was prepared from FR-900520 in a manner analogous to the compound of Example 8(c).

(b) 1.14-dihydroxy-12-T2-(cyclopentyl-3-carboxaldehyde)-1- methylvinyl]-23.25-dimethoxy-17-ethyl-13.19.21.27- tetramethyl-ll.28-dioxa-4-azatricyclor22.3.1.0 '91octacos-

2518-ene-2.3.10.16-tetraone

The product of step (a) was deprotected following the method of Example 8(d) to give the title compound. Example 20 1.14-dihvdroxy-12-r2-(cvclopentyl-3-methanol)-l-methylvinyll

-23.25-dimethoxy-17-ethyl-13.19.21.27-tetramethyl-ll.28- dioxa-4-azatricyclor22.3.1.04'9]octacos-18-ene-2.3.10.16- tetraone The product of Example 19 was reduced by the method of

Example 10(a) to give the title compound.

MS (plasma spray): 779 [M+NH4]+

Example 21

1.14-dihvdroxy-12-r2-ι*'cyclopentyl-3-carboxylic acid) -l-methylvinyll-23.25-dimethoxy-17-ethyl-13.19.21.27- tetramethyl-11.28-dioxa-4-azatricyclor22.3.1.04 '91octacos-

18-ene-2.3.10.16-tetraone

Oxidation of the product of Example 19(a) following the method of Example 12 and then deprotection following the method of Example 13 gave the title compound.

MS (FAB): 709 [M+Na]+

Example 22

1.14-dihydroxy-12-r2-(cyclopentyl-3-carboxylic acid methyl ester)-l-methylvinyll-23.25-dimethoxy-17-ethyl-13.19.21.27- o tetramethyl-11.28-dioxa-4-azatricycloT22.3.1.04'9]octacos-

18-ene-2.3.10.16-tetraone

Esterification of the product of Example 21 following the method of Example 14 yielded the title compound.

Example 23 5 l-14-dihydroxy-12-[2-(cyclopentyl-3-methyl propenoate)-1- methylvinyl]-23.25-dimethoxy-17-ethyl-13.19.21.27-tetra methyl-11.28-dioxa-4-azatricvclor22.3.1.04.91octacos-18-ene- 2.3.10.16-tetraone Wittig reaction on the product of Example 19(a) following the method of Example 17 and then deprotection following the method of Example 18 gave the title compound. MS (plasma spray): 834 [M+NH4]+ Example 24 l-Hvdroxy-12-r2-(cyclopentyl-3-carboxaldehyde)-l- methylvinyl]-23.25-dimethoxy-17-propyl-13.19.21.27- tetramethyl-11.28-dioxa-4-azatricyclor22.3.1.04'9]octacos- 18-ene-2.3.10.16-tetraone a) l-Hvdroxy-12-T2-(4-trifluoromethylsulphonyloxy-3- methoxycyclohexyl)-l-methylvinyll-23.25-dimethoxy-17-propγl- 13.19.21.27-tetramethyl-ll.28-dioxa-4-azatricyclo 22.3.1.0 ,9]octacos-18-ene-2.3.10.16-tetraone To a cold (-10°C) , stirred solution of l-hydroxy-12-[2-(4- hydroxy-3-methoxycyclohexyl)-1-methylvinyl]-23,25-dimethoxy- 17-propyl-13,19,21,27-tetramethyl-ll,28-dioxa-4-azatricyclo [22.3.1.04'9]octacos-18-ene-2,3,10,16-tetraone (Example 12, WO 89/05304) (0.3g) in dry dichloromethane (12ml) under nitrogen was added trifluoromethanesulphonic anhydride (0.1ml) until no starting material remained. Saturated aqueous sodium hydrogen carbonate solution was then added and the reaction mixture was extracted with diethyl ether. The ether extracts, after washing with saturated aqueous sodium hydrogen carbonate solution, dilute aqueous hydrochloric acid (IN) , and saturated aqueous sodium hydrogen carbonate solution, were dried (MgS04), filtered and concentrated in vacuo to give the title compound as an oil (300mg) . b) l-Hydroxy-12-r2-(cyclopentyl-3-carboxaldehyde)-l- methylvinyl1-23.25-dimethoxv-l7-.propvl-13.19.21.27- tetramethyl-ll.28-dioxa-4-azatricyclof22.3.1.04'91octacos- 18-ene-2.3.10.16-tetraone Silica (18g, Merck Kieselgel 60) was added to a solution of the product of step (a) (300mg) in dichloromethane (100ml) . Volatiles were then removed in vacuo at room temperature and the resulting freely flowing powder was stored at 8°C for 16 hours. The support was then washed with acetone containing triethylamine and the solvent was evaporated in vacuo to an oil. Chromatography on silica eluting with hexane in an acetone gradient then gave the title compound as a foam (51mg) . Example 25 l-Hvdroxy-12-r2-(cyclopentyl-3-methanol)-1-methylvinyl]- 23.25-dimethoxy-17-propyl-13.19.21.27-tetramethyl-ll.28- dioxa-4-azatricvclor22.3.1.04'9]octacos-18-ene-2.3.10.16- tetraone Reduction of the product of Example 24 following the method of Example 10(a) yielded the title compound. Example 26 l-Hvdroxy-12-r2-(cγclopentyl-3-carboxylic acid)-l-methyl vinyll-23.25-dimethoxy-17-propyl-13.19.21.27-tetramethyl- ll.28-dioxa-4-azatricyclof22.3.1.04 ' 9]octacos-18-ene- 2.3.10.16-tetraone

Oxidation of the product of Example 24 using the method of Example 12 gave the title compound, -gxap le 37 l-Hydroxy-12-r2-(cvclopentyl-3-carboxylic acid methylester) -1-methylvinyl]-23.25-dimethoxy-17-propyl-13.19.21.27-tetra methyl-11.28-dioxa-4-azatricyclor22.3.1.04 ' 9]octacos-18- ene-2.3.10.16-tetraone 5 Esterification of the product of Example 18 using diazomethane following the method of Example 14 gave the title compound. Example 28 l-Hydroxy-12-f2-(cyclopentyl-3-methyl prooenoate)-1-methyl in vinyl]-23.25-dimethoxy-17-propyl-13.19.21.27-tetramethyl- 11.28-dioxa-4-azatricyclor22.3.1.0 |,91octacos-18-ene- 2.3.10.16-tetraone

Wittig reaction with the product of Example 24 following the method of Example 17 yielded the title compound.

25 Example 29 l-Hvdroxy-12-r2-(cvclopentyl-3-carboxaldehyde)-1-methyl vinyl]-23.25-dimethoxy-17-ethyl-13.19.21.27-tetramethyl- ll.28-dioxa-4-azatricyclor22.3.1.0 '9]octacos-18-ene- 2.3.10.16-tetraone

2Q (a) l-Hydroxy-12-f2-(4-hvdroxy-3-methoxycyclohexyl)-l- methylvinyll-23.25-dimethoxy-17-ethyl-13.19.21.27-tetra methyl-11.28-dioxa-4-azatricycloT22.3.1.0 ' 9]octacosa- 14.18-ene-2.3.10.16-tetraone l,14-dihydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-l- methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-ll,28- dioxa-4-azatricyclo[22.3.1.04'9]octacos-18-ene-2,3,10,16- tetraone (FR-900520) (lOOmg) and p-toluenesulphonic acid (2mg) were dissolved in dry toluene (20ml) and were heated for 2 hours at 100"C under an atmosphere of nitrogen.

Removal of solvent in. vacuo and chromatography on silica eluting with hexane/acetone [2:1] gave the sub-title compound as a foam (80mg) . MS (FAB): 774.8 [M+H]+; 796.85 [M+Na]+; 858.71

[M+Rb]+.

13C NMR δ : (major rotamer) 201.15 (C16) ; 196.0 (C2) ;

169.2 (CIO); 165.1 (C3) ; 147.8 (C15) ; 138.0 (C19) ; 123.82

(C18) ; 97.88 (Cl) ; 84.05 (C34) . (b) l-Hydroxy-12-r2-(4-hydroxy-3-methoxycvclohexyl)-1- methylvinyl]-23.25-dimethoxy-17-ethyl-13.19.21.27-tetra methyl-11.28-dioxa-4-azatricyclof22.3.1.0 '9]octacos-18- ene-2.3.10.16-tetraone

A sample of the product from step (a) was dissolved in methanol (20ml) and 10% Pd-on-carbon (lOmg) was added. The mixture was stirred in an atmosphere of hydrogen for 1.5 hours at room temperature and pressure, and was then filtered through celite and evaporated to an oil in vacuo.

Column chromatography on silica eluting with hexane/acetone [2:1] gave the subtitle compound as a foam (50mg) .

MS (FAB): 776 [M+H]+; 798 [M+Na]+; 860 [M+Rb]+.

13C NMR δ : (major rotamer) 212.34 (C16) ; 196.42 (C2)

169.38 (CIO); 165.16 (C3); 138.9 (C19) ; 124.16 (C18) ; 97.41 (Cl) ; 84.19 (C34) . c) l-Hydroxy-12-f2-(cvclopent l-3-carboxaldehyde)-1- methvlvinvll-23.25-dimethoxv-17-ethvl-13.19.21.27- tetramethyl-ll.28-dioxa-4-azatricyclo[22.3.1.0 '9]octacos-

18-ene-2.3.10.16-tetraone The title compound was prepared from the product of step

(b) using the method of Example 1.

Example 30 l-Hydroxy-12-r2-(cvclopentyl-3-methanol)-1-methγlvinyl]- 23.25-dimethoxy-17-ethyl-13.19.21.27-tetramethyl-ll.28- dioxa-4-azatricγclor22.3.1.0 '9]octacos-18-ene-2.3.10.16- tetraone

Reduction of the product of Example 29 using the method of Example 10(a) yielded the title compound. Example 31 l-Hydroxy-12-r2-(cvclopentyl-3-carboxylic acid)-l-methyl vinyll-23.25-dimethoxy-17-ethyl-13.19.21.27-tetramethyl- ll.28-dioxa-4-azatricvclor22.3.1.0 '91octacos-18-ene- 2.3.10.16-tetraone Oxidation of the product from Example 29 following the method of Example 12 gave the title compound. Example 32 l-Hydroxy-12-r2-(cvclopentyl-3-carboxylic acid methyl ester)-l-methylvinyll-23.25-dimethoxy-17-ethyl-13.19.21.27- tetramathyl-11.28-dioxa-4-azatricyclof22.3.1.04'91octacos- 18-ene-2.3.10.16-tetraone

Esterification of the product of Example 31 using the method of Example 14 yielded the title compound. Example 33 l-Hydroxy-12-r2-(cyclopentyl-3-methyl propenoate)-l- methvlvinvl1-23.25-dimethoxv-17-ethvl-13.19.21.27- tetramethyl-ll.28-dioxa-4-azatricyclor22.3.1.0 '91octacos- 18-ene-2.3.10.16-tetraone Wittig reaction of the product of Example 29 following the method of Example 17 gave the title compound.

Example 34

17-Allvl-l-hvdroxv-12-r2-(cvclopentvl-3-carboxaldehvde) -l-methylvinyll-23.25-dimethoxy-13.19.21.27-tetramethyl-

11.28-dioxa-4-azatricyclor22.3.1.04'9]octacos-18-ene-

2.3.10.16-tetraone

The title compound was prepared from 17-allyl-l-hydroxy-

12-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylvinyl]-23,25- dimethoxy-13,19,21,27-tetramethyl-ll,28-dioxa-4-azatricyclo

[22.3.1.04'9]octacos-18-ene-2,3,10,16-tetraone (Example

17, WO 89/05304) using the method of Example 8(c).

Example 35

17-Allyl-l-hydroxy-12-r2-(cyclopentyl-3-methanol)-l- methylvinyl1-23.25-dimethoxy-13.19.21.27-tetramethyl-ll.28- dioxa-4-azatricvclor22.3.1.0 '91octacos-18-ene-2.3.10.16- tetraone

Reduction of the product from Example 34 following the method of Example 10(a) gave the title compound. Example 36

17-Allvl-l-hvdroxv-12-r2-(cvclopentyl-3-ca boxylic acid)

-l-methylvinyll-23.25-dimethoxy-13.19.21.27-tetramethyl-

11.28-dioxa-4-azatricvclor22.3.1.0 '91octacos-18-ene-

2.3.10.16-tetraone Oxidation of the product of Example 34 following the method of Example 12 yielded the title compound.

Example 37

17-Allvl-l-hvdroxv-12-r2-(cvclopentvl-3-carboxvlic acid methvl ester)-l-methvlvinvll-23.25-dimethoxv-13.19.21.27- tetramethyl-11.28-dioxa-4-azatricyclof22.3.1.04'91octacos- 18-ene-2.3.10.16-tetraone

Esterification of the product of Example 36 using the method of Example 14 gave the title compound.

Example 38

17-Allγl-l-hydroxy-12-r2-(cyclopentyl-3-methyl propenoate)

-l-methylvinyll-23.25-dimethoxv-13.19.21.27-tetramethvl-ll.2

8-dioxa-4-azatricvclor22.3.1.04'9]octacos-18-ene- 2.3.10.16-tetraone

Wittig reaction of the product of Example 34 following the method of Example 17 yielded the title compound.

Example 39

17-Allyl-1.14-dihvdroxy-12-r -(4(S)-hvdroxy-3- methoxycvclohexyl)-1-methylvinyll-23.25-dimethoxy-

13.19.21.27-tetramethyl-ll.28-dioxa-4-azatricvclo r22.3.1.04'9]octacos-18-ene-2.3.10.16-tetraone

(a) 17-Allyl-l-hvdroxy-12-r2-f4-tbutyldimethylsilyloxy-

3-methoxycyclohexyl)-1-methylvinyl1-14--butyldimethylsilyl oxy-23.25-dimethoxy-13.19.21.27-tetramethyl-ll.28-dioxa-4- azatricvclor22.3.1.0 •91octacos-18-ene-2.3.10.16-tetraone The subtitle compound was prepared as in Example 5(a) (1.28g) .

(b) 17-Allyl-l-hvdroxy-12-r2-(4-hvdroxy-3- methoxycyclohexyl)-1-methylvinyl]-14--butyldimethyl silyloxy-23.25-dimethoxy-13.19.21.27-tetramethyl-ll.28- dioxa-4-azatricyclor22.3.1.04'9]octacos-18-ene-2.3.10.16- tetraone A solution of the product from step (a) in methanol (100ml) containing pyridinium p-toluene sulphonate was stirred for 18 hours at room temperature. Volatiles were then removed in vacuo and the residue was dissolved in diethyl ether. The ethereal solution after washing with saturated aqueous sodium hydrogen carbonate solution, dilute aqueous hydrochloric acid (IN) , saturated aqueous sodium hydrogen carbonate solution and brine was dried (MgS04) , filtered and evaporated in vacuo to give the subtitle compound as a pale yellow foam (0.97g).

(c) 17-Allyl-l-hydroxγ-12-f2-(4-trifluoromethylsulphonyloxy -3-methoxycyclohexyl)-1-methylvinyl]-14--butyldimethyl silyloxy-23.25-dimethoxy-13.19.21.27-tetramethyl-ll.28-dioxa -4-azatricyclor22.3.1.0 '91octacos-18-ene-2.3.10.16- tetraone

To a cold (-10βC) stirred solution of the product of step (b) (0.97g) in dry dichloromethane (25ml) under nitrogen was added trifluoromethanesulphonic anhydride (0.1ml). After stirring for 15 minutes at -10"C saturated aqueous sodium hydrogen carbonate solution was added and the reaction mixture was extracted with diethyl ether. The ether extracts were then washed with saturated aqueous sodium hydrogen carbonate solution, dilute aqueous hydrochloric acid (IN) , saturated aqueous sodium hydrogen carbonate solution and brine before being dried (MgS0 ) , filtered and concentrated in vacuo to give the title compound as an oil (0.95g) .

(d) 17-Allyl-l-hydroxy-12-f2-(4(S)-hvdroxy-3-methoxycyclo hexvl)-l-methvlvinvll-14-tbutvldimethvlsilvloxy-23.25- dimethoxy-13.19.21.27-tetramethyl-ll.28-dioxa-4-azatricyclo [22.3.1.04 ' 91octacos-18-ene-2.3.10.16-tetraone Silica (55g, Merck Kieselgel 60) was added to a solution of the product of step (a) (0.9g) in dichloromethane (250 ml) . Volatiles were then removed in vacuo at room temperature and the resulting freely flowing powder was stored at 8βC for 16 hours. The support was then washed with ethyl acetate and 10% acetone in ethyl acetate containing 2,6-dimethyl pyridine. The combined organic extracts after washing with saturated aqueous sodium hydrogen carbonate solution, dilute aqueous hydrochloric acid (IN) , saturated aqueous sodium hydrogen carbonate solution and brine were dried (MgS04) , filtered and concentrated to an oil in vacuo. Chromatography on silica eluting with hexane in an acetone gradient then gave the title compound (0.28g) as a foam.

(e) 17-Allyl-l.14-dihvdroxy-12-r2-(4fS)-hvdroxy-3-methoxy cvclohexvl)-l-methvlvinvll-23.25-dimethoxy-13.19.21.27-tetra methyl-11.28-dioxa-4-azatricyclor22.3.1.0 '91octacos-18- ene-2.3.10.16-tetraone

To a solution of the product of step (d) (0.28g) in acetonitrile (10 ml) was added 40% aqueous hydrofluoric acid (2ml) . After stirring for 1 hour at room temperature the reaction mixture was poured into saturated aqueous sodium hydrogen carbonate solution and the mixture was extracted with diethyl ether. The organic extract was then dried (MgS04) , filtered and evaporated to an oil in vacuo. Chromatography on silica eluting with acetone/hexane [1:2] then gave the title compound (0.22g) as a foam.

MS (FAB): 888.43 [M+Rb]+ 13C NMR (CDC13) δ : (Major rotamer) 212.4 (C16) ; 196.1 (C2); 168.9 (CIO); 164.6 (C3); 138.8 (C19) ; 135.4 (C41) ; 132.3 (C29) ; 128.9 (C31) ; 122.3 (C18) ; 116.4 (C42) ;

96.8 (Cl) ; 81.9 (C34) ; 77.4 (C12) ; 75 (C23) ; 73.5 (C25) ; 72.7 (C24) ; 56.8 (C9) ; 52.7 (C17) ; 48.4 (C 20); 43.3 (C15) ; 39.6 (C13); 39.1 (C5) ; 35.6 (C21) ; 34.6 (C27) ; 30.4 (C32) ;

20.9 (C7) ; 20.2 (C44) ; 13.7 (C30) ; 9.4 (C39) . Example 40

1.14-Dihvdroxy-12-r2-(4 (S)-hydroxy-3-methoxycvclohexyl) -1- methylvinyl]-23 ,25-dimethoxy-17-ethyl-13.19.21.27-tetra methyl-11.28-dioxa-4-azatricyclor22.3.1.04'91octacos-18- ene-2.3.10.16-tetraone a) l-Hydroxy-12-r2-(4 (s)-hydroxy-3-methoxycyclohexyl) -1- methylvinyl]-l4--butyldimethylsilyloxy-23.25-dimethoxy-17- ethyl-13.19.21.27-tetramethyl-ll.28-dioxa-4-azatricyclo l"22.3.1.0 ',91octacos-18-ene-2.3.10.16-tetraone

Using the method of Example 39(a)-(d) the subtitle compound was prepared from l,l4-dihydroxy-12-[2-(4-hydroxy-3-methoxy cyclohexyl)-1-methylvinyl]-23,25-dimethoxy-17-ethyl- 13,19,21,27-tetramethyl-ll,28-dioxa-4-azatricyclo [22.3.1.04'9]octacos-18-ene-2,3,10,16-tetraone (FR-900520) . b) 1.14-Dihvdroxy-12-f2-(4(S)-hydroxy-3-methoxycyclohexyl) -1-methylvinyll-23.25-dimethoxy-17-ethyl-13.19.21.27- tetramethyl-11.28-dioxa-4-azatricvclor22.3.1.04'91octacos- 18-ene-2.3.10.16-tetraone

Using the method of Example 39(e) the title compound was prepared from the product of step (a) .

5 MS (FAB) : 876 [M+Rb]+ Example 41 l.l4-dihydroxv-12-r2-(4(S)-hvdroxv-3-methoxvcvclohexvl)-1- methylvinyl]-23.25-dimethoxy-17-propyl-13.19,21.27-tetra methyl-11.28-dioxa-4-azatricvclor22.3.1.04'91octacos-18- 0 ene~2.3.10.16-tetraone

To a solution of the product of Example 39 (20mg) in methanol (10ml) was added 10% Pd-on-C (5mg) and the resulting suspension was then stirred in an atmosphere of hydrogen for 2 hours at 0'C. The reaction mixture was then 5 filtered and volatiles were removed in vacuo. Chromatography on silica then gave the title compound as a foam (16mg) . MS (FAB): 890 [M+Rb]+ Example 42

20 17-Allvl-1.14-dihvdroxv-12-r2-(4-iodo-3-methoxvcvclohexvl) -1-methyIvinyl]-23.25-dimethoxy-13.19.21.27-tetramethyl- 11.28-dioxa-4-azatricvclor22.3.1.04'9]octacos-18-ene- 2.3.10.16-tetraone a) 17-Allyl-l-hydroxy-12-r2-(4-iodo-3-methoxycyclohexyl)

25 -1-methvlvinvl1-14--butvldimethvlsilvloxv-23.25-dimethoxv- 13.19.21.27-tetramethyl-ll.28-dioxa-4-azatricvclo r22.3.1.04'91octacos-18-ene-2.3.10.16-tetraone To a stirred, cold (-20"C) solution of the product of Example 39(d) (O.lg) in dry distilled dichloromethane (5ml) containing dry pyridine (0.4ml) under nitrogen was added trifluoromethanesulphonic anhydride (0.3ml). After 20 minutes at -20*C 2ml of saturated aqueous sodium hydrogen carbon ate solution was added and the reaction mixture was extracted with diethyl ether. The organic extracts were then washed with saturated aqueous sodium hydrogen carbonate solution, dilute aqueous hydrochloric acid (IN) and saturated aqueous sodium hydrogen carbonate solution before being dried (MgS04) , filtered and concentrated to an oil in vacuo. This was taken up in dry benzene (10ml) containing triethylamine (0.1ml) and was heated under reflux for one hour. Tetra-nbutylammonium iodide (200mg) was then added and heating was continued for a further 30 minutes. The reaction mixture was then cooled and poured into ether. The separated ether layer was washed with dilute aqueous hydrochloric acid (IN) , saturated aqueous sodium hydrogen carbonate, sodium thiosulphate solution and brine, before being dried (MgS04) , filtered and evaporated to an oil in vacuo. Chromatography on silica eluting with hexane in an increasing acetone gradient gave the subtitle compound (30mg) as a foam. b) 17-Allyl-1.14-dihydroxy-12-r2-.4-iodo-3-methoxycyclo hexyl)-l-methylvinyll-23.25-dimethoxy-13.19.21.27-tetra methyl-11.28-dioxa-4-azatricvclor22.3.1.04'9]octacos-18- ene-2.3.10.16-tetraone

To a solution of the product of step (a) (30mg) i acetonitrile (7ml) was added 40% aqueous hydrofluoric aci (lml) . After stirring for 1 hour at room temperature the reaction mixture was poured into saturated aqueous sodium hydrogen carbonate solution and the mixture was extracted with diethyl ether. The combined ether extracts were then washed with saturated aqueous sodium hydrogen carbonate solution and brine before being dried (MgS04) , filtered and concentrated to an oil in. vacuo. Chromatography on silica eluting with acetone/hexane [1:4] then gave the title compound (17mg) as a foam. MS (FAB): 870.74 [M-I+Rb]+; 997.15 [M+Rb]+

13C NMR (CDC13) δ : (Major rotamer) 213 (C16) ; 196.3 (C2) 169.1 (CIO); 164.8 (C3) ; 139.0 (C19) ; 135.7 (C41) ; 132.8 (C29) ; 129.1 (C31) ; 122.4 (C18) ; 116.7 (C18) ; 97 (Cl) ; 78.9 (C34); 76.6 (C12) ; 75.2 (C23) ; 73.8 (C25) ; 73.0 (C24) ; 70.2 (C14) ; 56.7 (C9) ; 52.8 (C17) ; 26.3 (C21) ; 9.4 (C39) . Example 43

17-Allyl-1.14-dihydroxy-12-r2-(3-methoxycyclohexyl)-l- methylvinyl]-23.25-dimethoxy-13.19.21.27-tetramethyl-ll.28- dioxa-4-azatricvclor22.3.1.04'91octacos-18-ene-2.3.10.16- tetraone a) 17-Allyl-l-hvdroxy-12-r2-(4-(imidazol-l-yl (thiocarbonyl)oxy)-3-methoxycyclohexyl)-1-methylvinyll-14- -butvldimethvlsilvloxv-ΣS.25-dimethoxv-13.19.21.27- tetramethyl-11.28-dioxa-4-azatricyclor22.3.1.04'91octacos- 18-ene-2.3.10.16-tetraone

A solution of the product of Example 39(b) (280mg) in dry distilled dichloroethane (40ml) containing l,l'-thiocarbonyldiimidazole (2g) was heated under reflux for 36 hours under an atmosphere of nitrogen. Volatiles were then removed in vacuo and the residue was chromatographed on silica eluting with dichloromethane/acetone [9:1] to give the subtitle compound (105mg) as a foam. b) 17-Allyl-1.2-dihvdroxy-12-r2-(3-methoxycvclohexyl)-l- methylvinyl1-14--butyldimethylsilyloxy-23.25-dimethoxy-

13.19.21.27-tetramethyl-ll.28-dioxa-4-azatricvclo 0 IJ _L_-_I_--L__04'91octacos-18-ene-3.10.16-trione

A solution of the product of step (a) (105mg) in dry benzene (25ml) containing AIBN (2,2 '-bisisobutyronitrile) (3mg) was heated to 40'C under nitrogen. Tributyltin hydride (0.1ml) was then added dropwise by syringe. The 5 temperature was then raised to 60βC over 5 minutes and a further 0.1 ml of tributyltin hydride was added. The temperature was then further raised to 90'C over 10 minutes and an additional 0.1ml of tributyltin hydride was added. After a further 10 minutes no starting material remained 0 and volatiles were removed in vacuo after cooling to room temperature. Chromatography on silica then gave the subtitle compound as an oil (85mg) . c) 17-Allyl-l-hydroxy-12-r2-(3-methoxycvclohexyl)-l- methylvinyl1-14--butyldimethylsilyloxy-23.25-dimethoxy-

25 13.19.21.27-tetramethyl-ll.28-dioxa-4-azatricvclo r22.3.1.04'91octacos-18-ene-2.3.10.16-tetraone A solution of the product of step (b) (85mg) in glacial acetic acid (10ml) containing copper (II) acetate (lg) was heated at 80βC for 5 minutes. The cooled reaction mixture was then poured into saturated aqueous sodium hydrogen carbonate solution and this was extracted with diethyl ether. The ether extracts were then dried (MgS04) , 5 filtered and concentrated to an oil in vacuo. Chromatography on silica eluting with acetone/hexane [2:5] then gave the subtitle compound as a foam (40mg) . d) 17-Allyl-1.14-dihydroxy-12-[2-(3-methoxycyclohexyl)-l- methylvinyll-23.25-dimethoxy-13.19.21.27-tetramethyl-ll.28- 0 dioxa-4-azatricyclor22♦3.1.0 '9]octacos-18-ene-2.3.10.16- tetraone

To a solution of the product of step (c) (40mg) in acetonitrile (8ml) was added 40% aqueous hydrofluoric acid (lml) . After stirring for 1 hour at room temperature the 5 reaction mixture was poured into saturated aqueous sodium hydrogen carbonate solution and the mixture was extracted with diethyl ether. The ether extracts were then dried (MgS04) , filtered and concentrated to an oil in vacuo. Chromatography on silica eluting with hexane in an o increasing acetone gradient then gave the title compound as a foam (20mg) .

MS (plasma spray): 752.73 [M+H-2H20]+; 770.76 [M+H-H20]+; 788.77 [M+H]+; 805.79 [M+NH4]+ 13C NMR (CDC13) δ : (Major rotamer) 212.9 (C16) ;

25196.2 (C2); 169 (CIO); 164.7 (C3) ; 139.0 (C19) ; 135.6 (C41) ; 131.6 (C29) ; 130.5 (C31) ; 122.4 (C18) ; 116.7 (C42) ; 97 (Cl) ; 78.9 (C34) ; 77 (C12) ; 75.2 (C23) ; 73.7 (C25) ; 72.8 (C24); 70.1 (C14) ; 56.4 (C9) ; 52.7 (C17) ; 48.5 (C20) ; 43.1 (C15 ) ; 39 . 7 (C13 ) ; 39 . 2 (C5 ) ; 26. 3 (C21) ; 21. 2 (C7 ) ; 20 . 5 (C44 ) ; 14 . 1 (C30) ; 9 .4 (C39 ) . Example 44

1.14-dihydroxy-12-r2-(3-methoxycvclohexyl)-1-methylvinyl]- 5 23.25-dimethoxy-17-ethyl-13.19.21.27-tetramethyl-ll.28- dioxa-4-azatricyclo[22♦3.1.04 •9]octacos-18-ene-2.3.10.16- tetraone a) l-Hydroxy-12- \2-(4-hydroxy-3-methoxγcyclohexyl)-1- methylvinyl]-14--butyldimethylsilyloxy-23.25-dimethoxy- 0 1 -ethyl-13.19.21.27-tetramethyl-ll.28-dioxa-4-azatricyclo [22.3.1.0 <,9]octacos-18-ene-2.3.10.16-tetraone The subtitle compound was prepared from l,14-dihydroxy-12- [2-(4-hydroxy-3-methoxycyclohexyl)-1-methylvinyl]-23,25- dimethoxy-17-ethyl-13,19,21,27-tetramethyl-ll,28-dioxa-4- 5 azatricyclo[22.3.1.04'9]octacos-18-ene-2,3,10,16-tetraone (FR-900520) following the method of Example 5(a) and 39(b). b) 1.14-dihydroxy-12-r2-(3-methoxycyclohexyl)-1- methylvinyl]-23.25-dimethoxy-17-ethyl-13.19.21.27- tetramethyl-ll.28-dioxa-4-azatricyclor22.3.1.04'91octacos- 0 18-ene-2.3.10.16-tetraone

The title compound was prepared from the product of step

(a) following the method of Example 43.

MS (plasma spray): 794 [M+NH4]+

Example 45 2 1.14-dihγdroxγ-12-r2-(3-methoxycyclohexyl)- -methylvinyl1-

23.25-dimethoxv-17-propvl-13.19.21.27-tetramethvl-ll.28- dioxa-4-azatricyclo[22.3.1.04'9]octacos-18-ene-2.3.10.16- tetraone To a solution of the product of Example 43 (28mg) in methanol (10ml) was added 10% Pd-on-C (5mg) and the resulting suspension was then stirred in an atmosphere of hydrogen for 2 hours at 0βC. The reaction mixture was then filtered and volatiles were removed in vacuo. Chromatography on silica then gave the title compound as a foam (25mg) .

MS (plasma spray): 808 [M+NH4]+ Example 46 17-Allyl-l-hydroxy-12-f2-(3-methoxycvclohexyl)-l-methyl vinyl]-23.25-dimethoxy-13.19.21.27-tetramethyl-ll.28-dioxa-4 -azatricvclor22.3.1.04'91octacos-18-ene-2.3.10.16-tetraone The title compound was prepared from 17-allyl-l-hydroxy-12- [2-(4-hydroxy-3-methoxycyclohexyl)-1-methylvinyl]-23,25- dimethoxy-13,19,21,27-tetramethyl-ll,28-dioxa-4-azatricyclo [22.3.1.04'9]octacos-18-ene-2,3,10,16-tetraone (Example 17, WO 89/05304) following the method of Example 43. Example 47 l-Hydroxy-12-f2-(3-methoxycyclohexyl)-1-methylvinyl]-23.25- dimethoxy-17-propyl-13.19.21.27-tetramethyl-ll.28-dioxa-4- azatricyclor22.3.1.04'91octacos-18-ene-2.3.10.16-tetraone The title compound was prepared from l-hydroxy-12-[2- (4-hydroxy-3-methoxycyclohexyl)-l-methylvinyl]-23,25- dimethoxy-17-propyl-13,19,21,27-tetramethyl-ll,28-dioxa-4- azatricyclo[22.3.1.04'9]octacos-18-ene-2,3,10,16-tetraone (Example 12, WO 89/05304) following the method of Example 43. Example 48 l-Hvdroxy-12-[2-(3-methoxycyclohexyl)-1-methylvinyl1-23.25- dimethoxy-17-ethyl-13.19.21.27-tetramethyl-ll.28-dioxa-4- azatricyclor22.3.1.0 ,91octacos-18-ene-2.3.10.16-tetraone a) 17-Ethyl-l-hvdroxy-12-r2-(4-hvdroxy-3-methoxycvclo hexyl)-1-methylvinyll-23.25-dimethoxy-13.19.21.27-tetra methyl-11.28-dioxa-4-azatricyclor22.3.1.04/9]octacosa-

14.18-diene-2.3.10.16-tetraone

17-Ethyl-l,14-dihydroxy-12-[2-(4-hydroxy-3-methoxycyclo hexyl)-1-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetra methyl-11,28-dioxa-4-azatricyclo[22.3.1.04'9]octacos-18- ene-2,3,10,16-tetraone (FR-900520) (lOOmg) and p-toluenesulphonic acid (2mg) were dissolved in dry toluene

(20ml) and were heated for 2 hours at 100βC under an atmosphere of nitrogen. Removal of solvent in vacuo and chromatography on silica eluting with hexane/acetone [2:1] gave the sub-title compound as a foam (80mg) .

MS (FAB): 774.8 [M+H]+; 796.85 [M+Na]+; 858.71

[M-r__b]+.

13C NMR δ : (major rotamer) 201.15 (C16) ; 196.0 (C2) ; 169.2 (CIO) ; 165.1 (C3); 147.8 (C15) ; 138.0 (C19) ; 123.82

(C18) ; 97.88 (Cl) ; 84.05 (C34) . b) 17-Ethyl-l-hvdroxy-12-r2-(4-hvdroxy-3- methoxycvclohexyl)-l-methylvinyl]-23.25-dimethoxγ- 13.19.21.27-tetramethyl-ll.28-dioxa-4-azatricyclo [22.3.1.04'9]octacos-18-ene-2.3.10.16-tetraone

A sample of the product from step (a) was dissolved in methanol (20ml) and 10% Pd-on-carbon (lOmg) was added. The mixture was stirred in an atmosphere of hydrogen for 1.5 hours at room temperature and pressure, and was then filtered through celite and evaporated to an oil in vacuo. Column chromatography on silica eluting with hexane/acetone [2:1] gave the title compound as a foam (50mg) .

5 MS (FAB): 776 [M+H]+; 798 [M+Na]+; 860 [M+Rb]+.

13C NMR 5: (major rotamer) 212.34 (C16) ; 196.42 (C2) ; 169.38 (CIO); 165.16 (C3) ; 138.9 (C19) ; 124.16 (C18) ; 97.41 (Cl) ; 84.19 (C34) . c) l-Hγdroxy-12-f2-(3-methoxycvclohexyl)-1-methγlvinyl]- 0 2 .25-dimethoxy-17-ethyl-13.19.21.27-tetramethyl-ll.28- dioxa-4-azatricyclo[22.3.1.0 '9]octacos-18-ene-2.3.10.16- tetraone

The title compound was prepared from the product of step (b) following the method of Example 43. 5 Example 49

17-Allyl-1.14-dihvdroxy-12-r2-(σyclohex-3-enyl)-l- methvlvinvl1-23.25-dimethoxy-13.19.21.27-tetramethvl- 11.28-dioxa-4-azatricvclor22.3.1.0 '91octacos-18-ene- 2.3.10.16-tetraone o a) 17-Allyl-l-hydroxy-12-r2-(4-iodo-3-methoxycyclohexyl) -l-methγlvinvn-14--butyldimethylsilyloxy-23.25-dimethoxy- 13.19.21.27-tetramethyl-ll.28-dioxa-4-azatricyclo r22.3.1.04'91octacos-18-ene-2.3.10.16-tetraone To a stirred, cold (-20"C) solution of 17-allyl-l-hydroxy-

25 12-[2-(4S)-hydroxy-3-methoxycyclohexyl)-1-methylvinyl]-14- -butyldimethylsilyloxy-23,25-dimethoxy-13,19,21,27- tetramethyl-ll,28-dioxa-4-azatricyclo[22.3.1.04'9]octacos- 18-ene-2,3,10,16-tetraone [the product of Example 39(d)] (0.54g) in dry distilled dichloromethane (25ml) containing dry pyridine (2ml) under nitrogen was added trifluoromethanesulphonic anhydride (1.2ml) . After 20 minutes at -20"C 10ml of saturated aqueous sodium hydrogen carbonate solution was added and the reaction mixture was extracted with diethyl ether. The organic extracts after washing with saturated aqueous sodium hydrogen carbonate solution, dilute aqueous hydrochloric acid (IN) and saturated aqueous sodium hydrogen carbonate solution were dried (MgS04) , filtered and concentrated to an oil in vacuo. This was taken up in dry benzene (30ml) containing dry pyridine (0.3ml) and tetra-nbutylammonium iodide

(l.Og) was added. After heating for 30 minutes under reflux the reaction mixture was cooled to room temperature and poured into ether. The separated ether layer was washed with dilute aqueous hydrochloric acid (IN) , saturated aqueous sodium hydrogen carbonate, sodium thiosulphate solution and brine, before being dried

(MgS04) , filtered and evaporated to an oil in vacuo. o Chromatography on silica eluting with acetone/hexane [1:4] then gave the title compound (500mg) as a diastereoisomeric mixture of iodides. [A smaller scale synthesis of the subtitle compound was described in Example 42(a)]. b) 17-Allγl-1.2-dihvdroxy-12-r2-(cvclohex-3-enyl)-l- 5 methylvinyl]-14--butyldimethγlsilyloxy-23.25-dimethoxy- 13.19.21.27-tetramethyl-ll.28-dioxa-4-azatricvclo r22.3.1.0 '91octacos-18-ene-3.10.16-trione To a solution of the product of step (a) (500mg) in glacial acetic acid (8ml) was added zinc dust. After stirring for 10 minutes at room temperature the reaction mixture was poured into saturated aqueous sodium hydrogen carbonate solution and this was extracted with diethyl ether. The ether extracts were then washed with saturated aqueous sodium hydrogen carbonate solution, dilute aqueous hydrochloric acid (IN) and saturated aqueous sodium hydrogen carbonate solution before being dried (MgS04) , filtered and concentrated in vacuo to give the subtitle compound (320mg) as an oil. c) l7-Allyl-l-hydroxy-12-r2-(cvclohex-3-enyl)-l- methylvinyl]-14--butyldimethylsilyloxy-23.25-dimethoxy- 13.19.21.27-tetramethyl-ll.28-dioxa-4-azatricvclo T22.3.1.04 91octacos-18-ene-2.3.10.16-tetraone A solution of the product of step (b) (320mg) in glacial acetic acid (8ml) containing copper (II) acetate was heated at 85*C for 5 minutes. After cooling to room temperature the reaction mixture was poured into saturated aqueous sodium hydrogen carbonate solution and this was then extracted with diethyl ether. The organic extract after washing with saturated aqueous sodium hydrogen carbonate solution, dilute aqueous hydrochloric acid (IN) and saturated aqueous sodium hydrogen carbonate solution was dried (MgS0 ) , filtered and concentrated to an oil in vacuo. Chromatography on silica eluting with hexane in an increasing acetone gradient then gave the title compound as a foam (280mg) . d) 17-Allvl-1.14-dihvdroxv-12-r2-fcvclohex-3-envl)-l- methylvinyll-23.25-dimethoxy-13.19.21.27-tetramethyl-

11.28-dioxa-4-azatricyclof22.3.1.0 '91octacos-18-ene-

2.3.10.16-tetraone

To a solution of the product from step (c) (280mg) in acetonitrile (20ml) was added 40% aqueous hydrofluoric acid (4ml) . After stirring for 30 minutes at room temperature the reaction mixture was poured into saturated aqueous sodium hydrogen carbonate solution and the mixture was extracted with diethyl ether. The combined ether extracts after washing with saturated aqueous sodium hydrogen carbonate solution were then dried (MgS0 ) , filtered and concentrated to an oil in vacuo. Chromatography on silica eluting with hexane in an increasing acetone gradient then gave the title compound as a foam (0.227g). MS (plasma spray): 720.52 [M+H-2H20]+; 738.-50 [M+H-H20]+; 756.58 [M+H]+; 773.53 [M+NH4]+ MS (FAB): 840.81 [M+Rb]+

13C NMR δ : (Major rotamer) 212.5 (C16) ; 196.2 (C2) ; 168.9 (CIO); 164.6 (C3) ; 138.8 (C19) ; 135.5 (C40) ; 131.4 (C31) ; 131.2 (C29); 126.9 (C34) ; 125.9 (C35) ; 122.4 (C18) ; 116.5 (C41) ; 96.9 (Cl) ; 77.4 (C12) ; 76.5 (C23) ; 73.5 (C25) ; 72.7 (C24) ; 69.9 (C14) ; 56.5 (C9) ; 52.7 (C17) ; 48.5 (C20) ; 43.4 (C15) ; 26.1 (C21) ; 20.3 (C43) ; 13.8 (C30) ; 9.4 (C38) . Example 50 1.14-Dihvdroxy-12-r2-(cvclohex-3-enyl)-l-methylvinyll-23.25- dimethoxy-17-ethyl-13.19.21.27-tetramethyl-ll.28-dioxa-4- azatricyclor22.3.1.04'9]octacos-18-ene-2.3.10.16-tetraone The title compound was prepared from the subtitle compound of Example 40(a) using the method of Example 49. MS (FAB): 829 [M+Rb]+. Example 51

1.14-dihydroxy-12-r2-(cvclohex-3-enyl)-l-methylvinyll-23.25- 5 dimethoxy-17-propyl-13.19.21.27-tetramethyl-ll.28-dioxa-4- azatricyclor22.3.1.04 91octacos-18-ene-2.3.10.16-tetraone a) l-Hvdroxy-12-r2-(4(S)-hydroxy-3-methoxycyclohexyl)- 1-methylvinyl1-14--butyldimethylsilyloxγ-23.25-dimethoxγ- 17-propyl-13.19.21.27-tetramethyl-ll.28-dioxa-4-azatricyclo 0 r22.3.1.04'9]octacos-18-ene-2.3.10.16-tetraone

The subtitle compound was prepared from 1,14-dihydroxy- 12-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylvinyl]-23,25- dimethoxy-17-propyl-13,19,21,27-tetramethyl-ll,28-dioxa-4- azatricyclo[22.3.1.04'9]octacos-18-ene-2,3,10,16-tetraone 5 (Example 10, WO 89/05304) following the method of Example 39(a)-(d). b) 1.l4-dihydroxγ-12-r2-(cyclohex-3-enyl)-l-methylvinyll- 23.25-dimethoxy-17-propyl-13.19.21.27-tetramethyl-ll ,28- dioxa-4-azatricvclor22.3.1.04'91octacos-18-ene-2.3.10.16-

2o tetraone

The title compound was prepared from the product of step

(a) following the method of Example 49.

MS (FAB) : 843 [M+Rb]+

Example 52 25 17-Allyl-l-hydroxy-12-r2-(cvclohex-3-enyl)-l-methylvinyll-

23.25-dimethoxγ-13.19.21.27-tetramethyl-ll.28-dioxa-4- azatricyclof22.3.1.04'91octacos-18-ene-2.3.10.16-tetraone

(a) χ7-Mlγl- -hydroxy-12-r?-(4(S)-ny^roxγ-3- methoxycyclohexyl)-l-methylvinyl]-23.25-dimethoxy- 13.19.21.27-tetramethyl-ll.28-dioxa-4-azatricyclo f22.3.1.o4'9]octacos-l8-ene-2.3.10.16-tetraone The subtitle compound was prepared from 17-allyl-l- hydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylvinyl] -23,25-dimethoxy-13,19,21,27-tetramethyl-ll,28-dioxa-4-aza tricyclo[22.3.1.04'9]octacos-18-ene-2,3,10,16-tetraone (Example 17, WO 89/05304) following the method of Example 39(a)-(d). (b) 17-Allvl-l-hvdroxv-l2-r2-(cvclohex-3-envl)-1-methyl vinyl]-23.25-dimethoxy-13.19.21.27-tetramethyl-ll.28-dioxa-4 -azatricyclor22.3.1.04/91octacos-18-ene-2.3.10.16-tetraone The title compound was prepared from the product of step (a) following the method of Example 49(a)-(c). Example 53 l-Hydroxy-12-r2-(cyclohex-3-enyl)-l-methylvinyl1-23.25- dimethoxy-17-ethyl-13.19.21.27-tetramethyl-ll.28-dioxa-4- azatricyclor22.3.1.04 •• 91octacos-18-ene-2.3.10.16-tetraone a) l-Hydroxy-12-f2-(4(S)-hydroxy-3-methoxycyclohexyl)- 1-methvlvinvl1-23.25-dimethoxy-17-ethyl-13.19.21.27- tetramethyl-ll.28-dioxa-4-azatricyclo[22.3.1.04.9]octacos- 18-ene-2.3.10.16-tetraone

The subtitle compound was prepared from 1-hydroxy- 12-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylvinyl]-23 ,25- dimethoxy-17-ethyl-13,19,21,27-tetramethyl-ll,28-dioxa-4-aza tricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetraone [the product of Example 48(b)] following the method of Example 39(a)-(d). MS (FAB): 861 [M+Rb]+ b) l-Hydroxy-12-[2-(cyclohex-3-enyl)-l-methylvinyl1-23.25- dimethoxγ-17-ethyl-13.19.21.27-tetramethyl-ll.28-dioxa-4- azatricyclor22.3.1.0 ' 1octacos-18-ene-2.3.10.16-tetraone The title compound was prepared from the product of step (a) following the method of Example 49(a)-(c). Example 54 l-Hydroxy-12-r2-(cyclohex-3-enyl)-1-methylvinyl1-23,25- dimethoxy-17-propyl-13.19.21.27-tetramethyl-ll.28-dioxa-4- azatricyclor22.3.1.04'91octacos-18-ene-2.3.10.16-tetraone a) l-Hydroxy-12-[2-(4-trifluoromethylsulphonyloxy-3- methoxycyclohexyl)-1-methylvinyl1-23.25-dimethoxy-17-propγl- 13.19.21.27-tetramethyl-ll.28-dioxa-4-azatricvclo f22.3.1.o4 ' 91octacos-18-ene-2.3.10.16-tetraone To a cold (-10βC) stirred solution of 1-hydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-1- methylvinyl]-23,25-dimethoxy-17-propyl-13,19,21,27- tetramethyl-ll,28-dioxa-4-azatricyclo[22.3.1.04'9]octacos- 18-ene-2,3,10,16-tetraone (Example 12, WO 89/05304) (0.3g) in dry dichloromethane (12ml) under nitrogen was added trifluoromethanesulphonic anhydride (0.1ml) until no starting material remained. Saturated aqueous sodium hydrogen carbonate solution was then added and the reaction mixture was extracted with diethyl ether. The ether extracts, after washing with saturated aqueous sodium hydrogen carbonate solution, dilute aqueous hydrochloric acid (IN) , and saturated aqueous sodium hydrogen carbonate solution, were dried (MgS04) , filtered and concentrated in vacuo to give the subtitle compound as an oil (300mg) . b) l-Hydroxy-12-r2-(4 (S)-hvdroxy-3-methoxycyclohexyl) -l- methylvinvl1-2 .25-dimethoxv-17-propvl-13.19.21.27- tetramethyl-11.28-dioxa-4-azatricvclor22.3.1.04'91octacos- 18-ene-? ,3 ,10,16-tetrgQne

Silica (18g, Merck Kieselgel 60) was added to a solution of the product of step (a) (300mg) in dichloromethane (100ml) . Volatiles were then removed in vacuo at room temperature and the resulting freely flowing powder was stored at 8βC for 16 hours. The support was then washed with acetone containing triethylamine and the solvent was evaporated in vacuo to an oil. Chromatography on silica eluting with hexane in an acetone gradient then gave the title compound as a foam (79mg) . MS (FAB): 772.83 [M+H-H20]+; 812.85 [M+Na]+; 874.65

[M+Rb]+

13C NMR (CDC13) δ : (Major rotamer) 212.2 (C16) 196.2 (C2); 169.2 (CIO); 165.1 (C3) ; 138.0 (C19) ; 131.3 (C29) ; 130.2 (C31) ; 124.1 (C18) ,* 97.2 (Cl) ; 75.3 (C23) ; 69 (C35) ; 56.1 (C9); 53.4 (C17) ; 49.1 (C20) ; 37.7 (C5) ; 34.9 (C13); 34.5 (C27); 30.5 (C32) ; 26.3 (C21) ; 20.8 (C7) ; 20.3 (C41). c) l-Hydroxy-12-r2-(cyclohex-3-enγl)-l-methylvinγl1-23.25- dimethoxy-17-propyl-13.19.21.27-tetramethyl-ll.28-dioxa-4- azatricyclof22.3.1.04'91octacos-18-ene-2.3.10.16-tetraone The title compound was prepared from the product of step (a) following the method of Example 49(a)-(c) .Example 55 1.14-Dihvdroxv-12-(2-cvclohexvl-l-methvlvinvl)-23.25- dimethoxv-17-propvl-13.19.21.27-tetramethvl-ll.28-dioxa-4- azatricyclor22♦3.1♦0 '91octacos-18-ene-2.3.10.16-tetraone To a solution of the product of Example 49 (60mg) in dry methanol (12ml) was added 10% Pd-on-C (lOOmg) and the 5 resulting suspension was stirred in an ice bath for one hour under an atmosphere of hydrogen. The reaction mixture was then filtered and concentrated to an oil in vacuo. Chromatography on silica eluting with hexane in an increasing acetone gradient then gave the title compound as Q a foam (44mg) .

MS (plasma spray): 724.56 [M+H-2H20]+; 742.54

[M+H-H20]+; 760.63 [M+H]+; 777.61 [M+NH4]+

MS (FAB): 844.86 [M+Rb]+ 13C NMR (CDC13) δ : (Major rotamer) 213.1 (C16) ; 5 195.9 (C2); 168.7 (CIO); 164.4 (C3) ; 138.0 (C19) ; 131.9 (C31); 130.3 (C29) ; 123 (C18) ; 96.7 (Cl) ; 74.9 (C23) ; 73.3 (C25) ; 72.5 (C24); 69.8 (C14) ; 56.3 (C9) ; 52.6 (C17) ; 48.3 (C20) ; 43.1 (C15) ; 39.3 (C13) ; 38.8 (C5) ; 36.2 (C32) ; 34.2 (C27) ; 20.1 (C43) ; 9.2 (C38) . 0 Example 56

1.14-Dihvdroxy-12-r2-cvclohexyl-l-methylvinyll-23.25- dimethoxy-17-ethyl-13.19.21.27-tetramethyl-ll.28-dioxa-4- azatricyclor22.3.1.04'9]octacos-18-ene-2.3.10.16-tetraone To a solution of the product of Example 50 (15mg) in dry __ methanol (4ml) was added 10% Pd-on-C (6mg) and the resulting suspension was stirred in an ice bath for one hour under an atmosphere of hydrogen. The reaction mixture was then filtered and concentrated to an oil in vacuo. Chromatography on silica eluting with hexane in an increasing acetone gradient then gave the title compound as a foam (14mg) . MS (FAB) : 831 [M+Rb]+ Example 57 l-Hvdroxy-12-r2-cvclohexvl-l-methvlvinvl1-23.25-dimethoxy- 17-ethyl-13r19.21.27-tetramethyl-ll.28-dioxa-4-azatricyclo f22.3.1.04'9]octacos-18-ene-2.3.10.16-tetraone The title compound was prepared from the product of Example 53 following the method of Example 55. Example 58 l-Hvdroxy-12-r2-cvclohexyl-l-methylvinγl]-23.25-dimethoxy- 17-propvl-13.19.21. 7-tetramethvl-ll.28-dioxa-4-azatricvclo r22.3.1.0 •9]octacos-18-ene-2.3.10.16-tetraone The title compound was prepared from the product of Example 54 following the method of Example 55. Example 59

17-Allyl-l.l4-dihydroxy-12-[2-(3-methoxycyclohexyl)-1- methylvinyl]-23.25-dimethoxy-13.19.21.27-tetramethyl-ll.28- o dioxa-4-azatricvclo[22.3.1.0 '9]octacos-18-ene-3.10.16- trione a) 17-Allyl-l-hvdroxy-12-r2-(4--butγldimethylsilyloxy- 3-methoxycyclohexyl)-l-methylvinyll-14- -butvldimethvlsilyloxy-ΣS.25-dimethoxv-13.19.21.27- 5 tetramethvl-11.28-dioxa-4-azatricvclor22.3.1.04 '91octacos- 18-ene-2.3.10.16-tetraone

To a cold (0'C) stirred solution of FR-900506 (lg) in dry dichloromethane (25ml) containing 2,6-dimethylpyridine (5ml) under nitrogen was added -butyldimethylsilyltriflate (2ml) until all the starting material had disappeared. The reaction mixture was then quenched with water and, after stirring for 5 minutes at room temperature, was extracted with diethyl ether. The ether extracts after washing with dilute aqueous hydrochloric acid (IN) (x2) , saturated aqueous sodium hydrogen carbonate solution and brine were dried (MgS04) , filtered and concentrated in vacuo to give the subtitle compound as an oil (1.28g) . b) 17-Allyl-l-hvdroxy-12-r2-(4-hvdroxy-3- ethoxycvclohexyl)-1-methylvinyl1-14-~butyldimethyl silyloxy-23.25-dimethoxy-13.19.21.27-tetramethyl-ll.28- dioxa-4-azatricyclor22.3.1.04'9]octacos-18-ene-2.3.10.16- tetraone

A solution of the product from step (a) in methanol (100ml) containing pyridinium p-toluene sulphonate was stirred for 18 hours at room temperature. Volatiles were then removed in vacuo and the residue was dissolved in diethyl ether. The ethereal solution after washing with saturated aqueous sodium hydrogen carbonate solution, dilute aqueous hydrochloric acid (IN) , saturated aqueous sodium hydrogen carbonate solution and brine was dried (MgS04) , filtered and evaporated in vacuo to give the subtitle compound as a pale yellow foam (0.97g). c) 17-Allvl-l-hvdroxv-12-T2-f4-(imidazol-1-yl (thiocarbonyl)oxy)-3-methoxycyclohexyl)-1-methylvinyl1-14- tbutvldimethvlsilvloxv-23.25-dimethoxv-13.19.21.27- tetramethyl-11.28-dioxa-4-azatricyclor22.3.1.04 • 9]octacos- 18-ene-2.3.10.16-tetraone

A solution of the product of step (b) (280mg) in dry distilled dichloroethane (40ml) containing l,l'-thiocarbonyldiimidazole (2g) was heated under reflux for 36 hours under an atmosphere of nitrogen. Volatiles were then removed in vacuo and the residue was chromatographed on silica eluting with dichloromethane/acetone [9:1] to give the subtitle compound (105mg) as a foam. d) 17-Allyl-1.2-dihvdroxy-12-r2-(3-methoxycyclohexyl)-l- methylvinyl]-14-~butyldimethylsilyloxy-23.25-dimethoxy-

13.19.21.27-tetramethyl-ll.28-diσxa-4-azatricyσlo [22.3.1.04'^octacσs-lS-ene-S,10,16-trione A solution of the product of step (c) (105mg) in dry benzene (25ml) containing AIBN (2,2'-bisisobutyronitrile) (3mg) was heated to 40"C under nitrogen. Tributyltin hydride (0.1ml) was then added dropwise by syringe. The temperature was then raised to 60"C over 5 minutes and a further 0.1 ml of tributyltin hydride was added. The temperature was then further raised to 90βC over 10 minutes and an additional O.lml of tributyltin hydride was added. After a further 10 minutes no starting material remained and volatiles were removed in vacuo after cooling to room temperature. Chromatography on silica then gave the subtitle compound as an oil (85mg) . e) 17-Allyl-l-hydroxy-12-r2-(3-methoxycyclohexyl)-l- methvlvinvll-14-tbutvldimethylsilyloxy-23.25-dimethoxy- 13.19.21.27-tetramethyl-ll.28-dioxa-4-azatricγclo r22.3.1.04'91octacos-18-ene-2.3.10.16-tetraone A solution of the product of step (d) (85mg) in glacial acetic acid (10ml) containing copper (II) acetate (lg) was heated at 80"C for 5 minutes. The cooled reaction mixture was then poured into saturated aqueous sodium hydrogen carbonate solution and this was extracted with diethyl ether. The ether extracts were then dried (MgS04) , filtered and concentrated to an oil in vacuo. Chromatography on silica eluting with acetone/hexane [2:5] then gave the subtitle compound as a foam (40mg) . f) 17-Allyl-1.14-dihydroxy-12-r2-(3-methoxycγclohexyl)-l- methylvinyl]-23.25-dimethoxy-13.19.21.27-tetramethyl-ll.28- dioxa-4-azatricyclo[22.3.1.04''9]octacos-18-ene-2.3.10.16- tetraone

To a solution of the product of step (e) (40mg) in acetonitrile (8ml) was added 40% aqueous hydrofluoric acid (lml) . After stirring for 1 hour at room temperature the reaction mixture was poured into saturated aqueous sodium hydrogen carbonate solution and the mixture was extracted with diethyl ether. The ether extracts were then dried (MgS04) , filtered and concentrated to an oil in vacuo. Chromatography on silica eluting with hexane in an increasing acetone gradient then gave the subtitle compound as a foam (20mg) .

MS (plasma spray): 752.73 [M+H-2H20]+; 770.76

[M+H-H20]+; 788.77 [M+H]+; 805.79 [M+NH4]+

13C NMR (CDC13) δ : (Major rotamer) 212.9 (C16) ; 196.2 (C2); 169 (CIO); 164.7 (C3) ; 139.0 (C19) ; 135.6 (C41) ; 131.6 (C29) ; 130.5 (C31) ; 122.4 (C18) ; 116.7 (C42) ; 97 (Cl) ; 78.9 (C34) ; 77 (C12) ; 75.2 (C23) ; 73.7 (C25) ; 72.8 (C24) ; 70.1 (C14) ; 56.4 (C9) ; 52.7 (C17) ,* 48.5 (C20) ; 43.1 5 (C15) ; 39.7 (C13) ; 39.2 (C5) ; 26.3 (C21) ; 21.2 (C7) ; 20.5 (C44); 14.1 (C30) ; 9.4 (C39) . g) 17-Allyl-l.14-dihydroxy-12-r2-(3-methoxycyclohexyl)-1- methylvinyll-23.25-dimethoxy-13.19.21.27-tetramethyl-ll.28- dioxa-4-azatricyclo[22.3.1.04-*9]octacos-18-ene-3.10.16- 0 trione

Hydrogen sulphide gas was bubbled through a solution of the product of step (f) (40mg) in pyridine (2ml) and dimethylformamide (0.1ml) for 2 hours at room temperature. After standing for 4 hours at room temperature dilute 5 aqueous hydrochloric acid was added and the reaction mixture was extracted with ethyl acetate. The ethyl acetate extract was then dried (MgS04) , filtered and concentrated in vacuo. Chromatography on silica eluting with ethyl acetate then gave the title compound as a foam 0 (25mg) .

MS (FAB): 858 (M+Rb)+; 796 (M+Na)+; 774 (M+H)+;

756 (M-OH)+ 13C NMR (CDC13) δ : 214.3 (C16) ; 174 (C3); 169.

(CIO); 141.2 (C19) ; 135.4 (C41) ; 131.6 (C29) ; 129.8 (C31) ; 25121.4 (C18); 116.6 (C42); 97.8 (Cl) ; 78.9 (C34) ; 48.4 (C20) ; 20.7 (C7); 14.3 (C30) ; 9.7 (C39) Example 60 17-Allyl-14-hvdroxy-12-r2-(4-hvdroxy-3-methoxycvclohexyl)-l- methylvinyl]-23.25-dimethoxy-13.19.21.27-tetramethyl-ll.28- dioxa-4-azatricyclof22.3.1.0 '9]octacos-18-ene-2.3.10.16- tetraone and 17-Allvl-14-hvdroxv-12-r2-(4-hvdroxv-3-metho>"'cyclohexvl)-1- methvlvinvll-23.25-dimethoxv-l.13.19.21.27-pentamethvl- 11.28-dioxa-4-azatricyclor22.3.1.0 ' 1octacos-18-ene- 2.3.10.16-tetraone a) 17-Allyl-l-chloro-14-hγdroxy-12-r2-(4-hydroxy-3- methoxycyclohexyl)-l-methylvinyll-23.25-dimethoxy-

13.19.21.27-tetramethvl-ll.28-dioxa-4-azatricvclo

T22.3.1.04'9]octacos-18-ene-2.3.10.16-tetraone

A solution of FR-900506 (500mg) in dry dichloromethane

(25ml) was added dropwise over 1 minute to a stirred, cool (0'C) solution of thionyl chloride (0.45ml) and pyridine (1.11ml) in dry dichloromethane (2Oml) under nitrogen. After 20 minutes, saturated aqueous sodium hydrogen carbonate solution was added and the mixture was stirred at room temperature for 20 minutes. The organic extract was then separated and washed with dilute aqueous hydrochloric acid (IM, 20ml), water (20ml) and brine (10ml) before being dried (MgS04) , filtered and evaporated in vacuo to give the sub-title compound as an an oil (512mg) . b) 17-Allyl-14-hvdroxy-12-[2-(4-hydroxy-3-methoxycyclo hexyl)-l-methylvinyl]-23.25-dimethoxy-13.19.21.27- tetramethyl-11.28-dioxa-4-azatricyclo[22.3.1.0 '9]octacos-

18-ene-2.3.10.16-tetraone and 17-Allyl-14-hydroxy-12-r2-(4-hydroxy-3-methoxycvclohexyl)-l- methylvinyll-23.25-dimethoxy-l.13.19.21.27-pentamethyl- 11.28-dioxa-4-azatricyclo[22.3.1.04,,91octacos-18-ene- 2.3.10.16-tetraone To a cold (-50'C), stirred suspension of copper (I) iodide (463mg) in dry diethyl ether (20ml) under nitrogen was added a dilute (1.1M) solution of methyl lithium in ether (4.42ml). After stirring for 30 minutes at -40°C the reaction mixture was cooled to -70*C and a solution of the product from step (a) (400mg) in dry ether (20ml) was added dropwise. After stirring for 20 minutes, saturated aqueous ammonium chloride solution was added and the reaction mixture was allowed to warm to room temperature. The ethereal layer was then separated and was washed with water (20ml) and brine (20ml) before being dried (MgS04) , filtered and evaporated to an oil in vacuo. Chromatography on silica then gave a first isomer of the first title compound (Isomer A, 5mg) , a second isomer of the first title compound (Isomer B, 20mg) , and the second title compound (4.5mg). MS (FAB):

Isomer A - 770.8 [M+H-H20]+; 788.8 [M+H]+; 810.8 [M+Na]+; 872.6 [M+Rb]+

Isomer B - 872.4 [M+Rb]+ 2nd title compound - 784.8 [M+H-H20]+; 802.8 [M+H]+; 824.8 [M+Na]+; 886.5 [M+Rb]+ ^•C NMR (CHC13) δ : Isomer A - 211.4 (C16) ; 200.7 (C2) ; 169 (CIO); 165.6 (C3 ) ; 139. 6 (C19) ; 135.7 (C41) ; 131.9 (C31) ; 131.2 (C29) ;

122.4 (C18); 116.5 (C42) ; 84.2 (C34) ; 80.5 (C12) 78.3

(Cl) ; 76.9 (C23); 75.2 (C24) ; 74.9 (C25) ; 73.5 (C35) 68.5

(C14) ; 53.4 (C17) ; 52 (C9) ; 47.7 (C20) ; 45.5 (C15) 44.3 (C5) ; 40.1 (C13); 35.2 (C40) ; 34.9 (C32) ; 34.8 (C22) 34.6

(C33); 32.7 (C26) ; 31.5 (C27) ; 31.2 (C36) ; 30.5 (C37) 27.1 (C21) ; 25.8 (C8) ; 24.9 (C6) ; 20.8 (C7) ; 20.5 (C44) 17.1 (C43); 16.4 (C47) ; 13.3 (C30) ; 10.1 (C39) ISOmer B - 213.2 (C16) ; 197 (C2); 170.2 (CIO); 163.8 (C3); 137.3 (C19) ; 135.2 (C41) ; 131.9 (C29) ; 128.5 (C31) ; 123.4 (C18) ; 116.7 (C42) ; 84.1 (C34) ; 83.5 (Cl) ; 79.3 (C12) ; 70.2 (C14) ; 55.9 (C9) ; 51.9 (C17) ; 49.4 (C20) ; 44.7 (C15) ; 40 (C5) ; 40.1 (C13) ; 38.5 (C40) ; 10.1 (C39) 2nd title compound - 212.4 (C16) ; 203.3 (C2) ; 169.4 (CIO); 167 (C3); 139.1 (C19) ; 135.6 (C41) ; 131.8 (C29) ; 129.7 (C31) ; 123 (C18) ,* 116.6 (C42) ; 84.2 (C34) ; 82.9 (Cl) ; 77.3 (C12); 69.7 (C14) ; 52.5 (C17) ; 52 (C9) ; 47.7 (C20) ; 45.2 (C15) ; 44 (C5) ; 39.9 (C13) ; 14.1 (C48) ; 10 (C39) .

Isomers A and B differ in their stereochemistry at Cl. Example 61

17-Allyl-l.14-dihydroxy-12-f2-(cγclopentyl-3-methanol(methyl ether) )-1-methylvinyl]-23.25-dimethoxy-13.19.21.27-tetra methyl-11.28-dioxa-4-azatricvclof22.3.1.0 '9]octacos-18- ene-2.3.10.16-tetraone

To a solution of the compound of Example 10(a) (73mg) in diethyl ether (2ml) containing boron trifluoride diethyl etherate (0.1ml) was added an ethereal solution of diazomethane. After standing for 30 minutes at room temperature volatiles were removed in vacuo and the residue was chromatographed on silica eluting with hexane/acetone [4:1] to give 17-allyl-l-hydroxy-12-[2-(cyclopentyl-

5 3-methanol(methylether))-1-methylvinyl]-23,25-dimethoxy-14- -butyldimethylsilyloxy-13,19,21,27-tetramethyl-ll,28-dioxa -4-azatricyclo[22.3.1.04'9]octacos-18-ene-2,3,10,16- tetraone (20mg) as a foam. This was dissolved in acetonitrile (5ml) and 40% aqueous hydrofluoric acid 0 (0.5ml) was then added. After stirring for 75 minutes at room temperature the reaction mixture was poured into ethyl acetate and was washed with saturated aqueous sodium hydrogen carbonate solution and brine before being dried, (MgS04) , filtered and evaporated to an oil in vacuo. 5 Chromatography on silica eluting with acetone/hexane [1:3] then gave the title compound (lOmg) as a foam. 13C NMR (CDC13) δ : (Major rotamer) 213.8 (C16) ; 196.2 (C2); 168.9 (CIO); 164.9 (C3) ; 138.9 (C19) ; 135.6 (C40) ; 122.5 (C18) ; 116.6 (C41) ; 97 (Cl) ; 77.4 (C12) ; 75.2 (C23) ; 0 70.1 (C14) ; 58.8 (cyclopentylCH2OCH3) ; 56.3 (C9) ; 52.8 (C17) ; 48.6 (C20) ; 29.7 (C8) ; 26.3 (C21) ; 24.6 (C6) ; 21.1 (C7); 20.4 (C43); 14.1 (C30) ; 9.5 (C38) MS (FAB): 872 [M+Rb]+; 810 [M+Na]+; 788 [M+H]+. Example 62

25 17-Allyl-l.14-dihydroxy-12-[2-(4-amino-3-methoxycyclohexyl)- l-methylvinyll-23.25-dimethoxy-13.19.21.27-tetramethyl- ll.28-dioxa-4-azatricyclor22.3.1.04'91octacos-18-ene- 2.3.10.16-tetraone a) 17-Allyl-l-hvdroxy-12-r2-(4-azido-3-methoxycyclohexyl)- 1-methylvinyl1-23.25-dimethoxy-14--butyldimethγlsilyloxy-

13.19.21.27-tetramethyl-ll.28-dioxa-4-azatricvclo f22.3.1.04'9]octacos-18-ene-2.3.10.16-tetraone To a stirred, cold (-20'C) solution of the product of Example 39(b) (0.19g) in dry distilled dichloromethane (7ml) containing dry pyridine (0.63ml) under nitrogen was added trifluoromethanesulphonic anhydride (0.41ml). After 20 minutes at -20"C saturated aqueous sodium hydrogen carbonate solution (3ml) was added and the reaction mixture was extracted with diethyl ether. The organic extracts were then washed with saturated aqueous sodium hydrogen carbonate solution, dilute aqueous hydrochloric acid (IN) , and saturated aqueous sodium hydrogen carbonate solution before being dried (MgS04) , filtered and concentrated to an oil in vacuo. This material was dissolved in dry DMF (5ml) and sodium azide (0.5g) was added. After stirring for 30 minutes at room temperature the reaction mixture was poured into water and this was then extracted with ethyl acetate. The organic extract after washing with brine was dried (MgS04) , filtered and concentrated to an oil in vacuo. Chromatography on silica then gave the subtitle compound (83mg) as a foam. b) 17-Allyl-l-hydroxy-12-[2-(4-amino-3-methoxycyclohexyl)- 1-methylvinyll-23.25-dimethoxγ-14--butyldimethylsilyloxy-

13.19.21.27-tetramethyl-ll.28-dioxa-4-azatricvclo r22.3.1.04'9]octacos-18-ene-2.3.10.16-tetraone

To a stirred solution of the product of step (b) (50mg) in dry, distilled methanol (5ml) under nitrogen was added 1,3-propanedithiol (0.03ml) and triethylamine (0.04ml) . After stirring for 1 hour at room temperature the reaction mixture was columned on silica eluting with hexane/acetone [3:1] to give the subtitle compound as a foam (37mg) .

13C NMR (CDC13) <S: (Major rotamer) 209.6 (C16) ; 196.5 (C2) ; 169.1 (CIO); 164.7 (C3); 138.5 (C19) ; 135.7 (C41) ; 133.3 (C29) ; 128.3 (C31) ; 123.2 (C18) ; 116.6 (C42) ; 97.6 (Cl) ; 82.4 (C34); 56.4 (C9) ; 53.7 (C17) ; 49.3 (C20) ; 43.7 (C15) ; 40 6 (C13); 39.2 (C5) ; 10.5 (C39) . MS (FAB): 1001.6 [M+Rb]+ c) 17-Allyl-1.14-dihydroxy-12-[2-(4-amino-3-methoxycvclo hexyl)-1-methylvinyl1-23.25-dimethoxy-13.19.21.27-tetra methyl-11.28-dioxa-4-azatricyclo[22.3.1.04'9]octacos-18- ene-2.3.10.16-tetraone

To a solution of the product of step (b) (35 mg) in acetonitrile (7ml) was added 40% aqueous hydrofluoric acid (0.5ml). After stirring for 2.5 hours at room temperature the reaction mixture was poured into ethyl acetate and the separated organic extract was then washed with saturated aqueous sodium hydrogen carbonate solution and brine before being dried (MgS04) , filtered and evaporated to an oil in vacuo. Column chromatography on silica eluting with hexane/acetone [2:1] then gave the title compound (15mg) as a foam.

13 JC, NMR (CDCI3) δ : (Major rotamer) 212.9 (C16) ; 196.2 (C2); 169.1 (CIO); 164.8 (C3) ; 139.1 (C19) ; 135.7 (C41) ; 132.9 (C29); 128.5 (C31) ; 122.6 (C18) ; 116.8 (C42) ; 97.2 (Cl) ; 82.9 (C34) ; 78 (C12) ; 75.4 (C23) ; 73.8 (C25) ; 73.0 (C2 4); 70.2 (C14) ; 57.1 (C9) ; 53.1 (C17) ; 48.7 (C20) ; 43.3 (C15) ; 39.8 (C13) ; 39.4 (C5) ; 24.1 (C6) ; 21.3 (C7) ; 20.6 (C44) ; 14.2 (C30) ; 9.7 (C39) . MS (FAB): 888.5 [M+Rb]+; 826.7 [M+Na]+; 786.7 [M+H-H20]+ Example 63

17-Allyl-l.14-dihvdroxy-12-r2-(4-acetamido-3-methoxycγclo hexyl)-1-methylvinyl1-23.25-dimethoxγ-13.19.21.27-tetra methyl-11.28-dioxa-4-azatricvclor22.3♦1.04 * 91octacos-18- ene-2.3.10.16-tetraone a) 17-Allyl-l-hvdroxγ-12-r2-(4-acetamido-3-methoxycvclo hexyl)-l-methylvinyll-23.25-dimethoxy-14--butyldimethγl silyloxy-13.19.21.27-tetramethyl-ll.28-dioxa-4-azatricyclo r22.3.1.04'9]octacos-l8-ene-2.3.10.16-tetraone

To a solution of the product of Example 62(b) (20mg) in dry dichloromethane (3ml) was added pyridine (0.1ml) and acetyl chloride (0.1ml). After stirring for 10 minutes at room temperature the reaction mixture was poured into water and this was then extracted with diethyl ether. The organic extract was then washed with dilute aqueous hydrochloric acid and brine before being dried (MgS0 ) , filtered and evaporated to an oil in vacuo. Chromatography on silica eluting with hexane/acetone [3:1] then gave the subtitle compound (15mg) as an oil. b) 17-Allvl-1.14-dihvdroxv-12-r2-(4-acetamido-3-methoxv cyclohexyl)-1-methylvinyll-23.25-dimethoxy-13.19.21.27-tetra methyl-11.28-dioxa-4-azatricyclo[22.3♦1.04'91octacos-18- ene-2.3.10.16-tetraone

A portion of the product from step (a) (13mg) was dissolved in acetonitrile (4ml) and to this was added 40% aqueous hydrofluoric acid (0.1ml). After stirring for 2 hours at room temperature the reaction mixture was poured into ethyl acetate and the separated organic extract was then washed with water, saturated aqueous sodium hydrogen carbonate solution and brine before being dried (MgS04) , filtered and evaporated to an oil in vacuo. Column chromatography o silica eluting with hexane/acetone [2:1] then gave the title compound (8mg) as a foam.

13C NMR (CDC13) δ (Major rotamer) 212.4 (C16) ; 196.2 (C2); 169 (CIO); 164.7 (C3); 139 (C19) ; 135.5 (C41) ; 122.4 (C18); 116.7 (C42) ; 97 (Cl) ; 9.4 (C39) ~H NMR (CDCI3) δ : 2.01 [3H,S,NHC0CH.3] MS (FAB): 930.5 [M+Rb]+; 868.9 [M+Na]+ Example 64

17-Allyl-1.14-dihvdroxy-12-r2-(4-formyloxy-3-methoxycvclo hexyl)-l-methylvinyll-23.25-dimethoxy-13.19.21.27-tetra methyl-11.28-dioxa-4-azatricvclor22.3.1.0 '9]octacos-18- ene-2.3.10.16-tetraone

To a solution of the compound of Example 39(c) (1.103g) in dry DMF (20ml) was added sodium azide (2.58g). After stirring for 2 hours at room temperature the reaction mixture was poured into water and this was then extracted with ethyl acetate. The organic extract after washing with brine was dried (MgS04) , filtered and concentrated to an oil in vacuo. Chromatography on silica eluting with hexane/acetone [3:1] then gave 17-allyl-l-hydroxy-12-[2-(4- formyloxy-3-methoxycyclohexyl)-1-methylvinyl]-23,25- dimethoxy-14-tbutyldimethylsilyloxy-13,19,21,27-tetra methyl-11,28-dioxa-4-azatricyclo[22.3.1.04'9]octacos-18- ene-2,3,10,16-tetraone (115mg) as a foam. A portion of this (71mg) was dissolved in acetonitrile (14ml) and to this was added 40% aqueous hydrofluoric acid (0.5ml). After stirring for 3.5 hours at room temperature the reaction mixture was poured into ethyl acetate and the separated organic extract was then washed with water, saturated aqueous sodium hydrogen carbonate solution and brine before being dried (MgS04) , filtered and evaporated in vacuo to an oil. Column chromatography on silica eluting with hexane/acetone [2:1] then gave the title compound (19mg) as a foam.

13C NMR (CDC13) δ : (Major rotamer) 212.7 (C16) ; 196.2 (C2); 169.2 (CIO); 164.8 (C3) ; 160.6 (OCHO-) ; 138.9 (C19) ;

135.5 (C41) ; 132.4 (C29) ; 129.5 (C31) ; 122.4 (C18) ; 116.6 (C42); 96.9 (Cl) ; 78.7 (C34) ; 77.3 (C12) ; 75.1 (C23) ; 72.8 (C24) ; 70 (C14); 56.6 (C9) ; 52.7 (C17) ; 48.5 (C20) ; 43 (C15) ; 39.6 (C13); 39.2 (C5) ; 28.2 (C8) ; 26.2 (C21) ; 24.5 (C6) ; 21.1 (C7) ; 20.4 (C44) ; 14.1 (C30) ; 9.3 (C39) . MS (FAB): 916.2 [M+Rb]+; 854.5 [M+Na]+; 832.6 [M+H]+;

814.6 [M+H-H20]+ Example 65

17-Allyl-1.14-dihvdroxy-12-r2-(3-oxo-cyclohexyl)-l-methyl vinyll-23.25-dimethoxy-13.19.21.27-tetramethyl-ll.28-dioxa- 4-azatricvclor22.3♦1.04'91octacos-18-ene-2.3.10.16- tetraone and

17-Allyl-1.14-dihvdroxy-12-r2-(3-methoxy-cvclohex-4-enyl)-l- methylvinyll-23.25-dimethoxy-13.19.21.27-tetramethyl-ll.-28- dioxa-4-azatricyclor22.3.1.04'91octacos-18-ene-2.3.10.16- tetraone

Silica (220g, Merck Kieselgel 60, Art. 15111) was added to a solution of the compound of Example 39(c) (250ml). Volatiles were then removed in vacuo at room temperature and the resulting freely flowing powder was stored at 8*C for 16 hours. The support was then washed with ethyl acetate and 10% acetone in ethyl acetate containing 2,6-dimethylpyridine. The combined organic extracts after washing with saturated aqueous sodium hydrogen carbonate solution, dilute aqueous hydrochloric acid (IN) , saturated aqueous sodium hydrogen carbonate solution and brine were dried, (MgS04), filtered and concentrated to an oil in vacuo. Chromatography on silica eluting with hexane in an acetone gradient then gave the compound of Example 39(d) (l«12g) as a foam. Further elution then gave the compound of Example 8(c) (0.5g) as a foam.

Mixed fractions were then combined, treated with 40% aqueous hydrofluoric acid as above, and re-chromatographed on silica eluting with ethyl acetate to give the first title compound (200mg) .

13C NMR (CDC13) δ : (Major rotamer) 212.5 (C16) ; 210.7 (C34); 196.2 (C2); 169 (CIO); 164.7 (C3) ; 139 (C19) ; 135.5 (C41) ; 133.1 (C29) ; 129 (C31) ; 122.5 (C18) ; 116.7 (C42) 97.1 (Cl) ; 77.6 (C12) ; 75.2 (C23) ; 73.7 (C25) ; 72.8 (C 24) 69.9 (C14) ; 56.3 (C9) ; 52.9 (C17) ; 48.6 (C20) ; 47.6 (C33) 43.5 (C15) ; 41.2 (C35) ; 39.7 (C13) ; 37.9 (C32) ; 26.2 (C21) 25.8 (C8) ; 24.5 (C6) ; 21.1 (C7) ; 20.4 (C44) ; 13.8 (C30) 9.7 (C39) .

MS (FAB): 856 [M+Rb]+; 794 [M+Na]+; 736 [M+H-2H20]+ Further elution then gave the second title compound. 13 NMR (CDC13): «5 (Major rotamer) 212.6 (C16) ; 196.2 (C2) ; 168.9 (CIO); 164.6 (C3) ; 139.7 (C19) ; 135.5 (C41) ; 132.3 (C29) ; 129.9 (C31) ; 122.3 (C18) ; 116.5 (C42) ; 128.5 (C35) ; 128.1 (C36) ; 96.9 (Cl) ; 73.5 (C25) ; 72.7 (C24) ; 70.5 (C14); 56.5 (C9) ; 52.7 (C17) ; 48.4 (C20) ; 27.6 (C8) ; 26.1 (C21) ; 24.4 (C6) ; 21 (C7) ; 20.3 (C44) ; 14 (C30) ; 9.3 (C39) . MS (FAB): 870 [M+Rb]+; 808 [M+Na]+ Example 66

17-Allvl-l.14-dihvdroxv-12-r2-.cvclopentvl-3-carboxvlic acid morpholine amide)-1-methylvinyl]-23.25-dimethoxy -13.19.21.27-tetramethyl-ll.28-dioxa-4-azatricyclo r22.3.1.0 '91octacos-18-ene-2.3.10.16-tetraone

To a solution of the product of Example 13 was added morpholine (0.03ml) followed by triethylamine (0.03ml) and 2-chloro-1-methylpyridinium tosylate (70mg) . After stirring for 1 hour at room temperature a further portion of the tosylate (40mg) was added and stirring was continued for 5.5 hours at room temperature. Additional triethylamine (0.03ml) and morpholine (0.03ml) was then added and the reaction mixture was stirred overnight at room temperature. The reaction was then quenched with dilute aqueous hydrochloric acid (2M, 10ml) and the mixture was extracted with ethyl acetate. The organic extracts were then washed with saturated aqueous sodium hydrogen carbonate solution and brine before being dried (MgS04) , filtered and evaporated to an oil in vacuo. Chromatography on silica eluting with hexane in an increasing acetone gradient then gave the title compound (30mg) as a foam. MS (FAB): 941.4 [M+Rb]+; 880.2 [M+Na]+; 858.4 [M+H]+; 840.4 [M+H-H20]+

13C NMR (CDC13) <S: (Major rotamer) 212.4 (C16) ; 196.2 (C2) ; 174.6 (cyclopentylCO) ; 169.1 (CIO); 164.7 (C3) ; 138.9 (C19) ; 135.6 (C40) ; 132.5 (C29) ; 131.3 (C31) ; 122.7 (C18) ; 116.7 (C41) ; 97.1 (Cl) ; 70.0 (C14) ; 67 and 66.8 (morpholine CH20) ; 56.3 (C9) ; 52.9 (C17) ; 48.8 (C20) ; 46.1 and 42.3 (morpholineCH2N) ; 27.8 (C8) ; 26.2 (C21) ; 24.5 (C6) ; 21.0 (C7) ; 20.3 (C43) ; 14.1 (C30) ; 9.9 (C38)

Claims

CLAIMS :
1. A compound of formula I,
wherein R1 represents H, OH or alkoxy; R2 represents H; in addition, R1 and R2 may together represent a second bond between the carbon atoms to which they are attached; R3 represents methyl, ethyl, propyl or allyl; R4 represents H, OH, alkyl, alkoxy, halogen, amino, S-alkyl, NHCHO or NHCO-alkyl; n represents 1 or 2;
X represents O, (H,OH) , (H,H) or =NH; and Y represents a cyclic group of formula II,
in which R5 represents (H,H) , (H,OH) , (H,methoxy) or 0; R6 represents H, (R)-OH, (S)-OH, alkoxy, amino, alkylamino, alkanoylamino, formyloxy or halogen; R7 represents H; and in addition R5 and R6 may together represent a second bond between the carbon atoms to which they are attached; or R6 and R7 may together represent a second bond between the carbon atoms to which they are attached; or a cyclic group of formula III,
in which R8 represents alkyl substituted by one or more groups selected from OH, alkoxy, =0, and C02H; or alkenyl optionally substituted by one or more groups selected from OH, =0, or C02H; provided that a) when n represents 1; R1 represents OH; R3 represents allyl; R4 represents OH; R5 represents (H,methoxy) ; and R6 represents (R)-OH; then X does not represent 0; b) when n represents 2; i) R1 represents OH; R3 represents methyl, ethyl, allyl or propyl; R4 represents OH; R5 represents (H,methoxy) ;. and R6 represents (R)-OH; then X does not represent 0; ii) when R1 and R2 together represent a second bond between the carbon atoms to which they are attached or each represent H; R3 represents allyl or propyl; R4 represents OH; R5 represents (H,methoxy) ; and R6 represents (R)-OH; then X does not represent 0; iii) when R1 represents OH, methoxy or together with R2 it represents a second bond between the carbon atoms to which they are attached; R3 represents allyl; R4 represents OH; R5 represents (H,methoxy) ; and R6 represents methoxy; then X does not represent 0; iv) when R1 represents H or OH; R3 represents allyl; R4 represents OH; R5 represents (H,methoxy) ; and R6 represents (R)-OH; then X does not represent (H,OH) ; v) when R1 represents H; R3 represents propyl; R4 represents OH; R5 represents (H,OH) ; and R6 represents (R)-OH; then X does not represent 0; vi) when R1 represents OH; R3 represents ethyl; R4 represents OH; R5 represents (H,methoxy) ; and R6 represents (R)-OH; then X does not represent (H,0H) ; vii) when R1 and R2 together represent a second bond between the carbon atoms to which they are attached or each represent H; R3 represents ethyl; R4 represents OH; R5 represents (H,methoxy) ; and R6 represents (R)-OH; then X does not represent O; viii) when R1 represents OH; R3 represents allyl; R4 represents OH; R5 represents (H,0H) or (H,methoxy) ; and
R6 represents (R)-OH; then X does not represent (H,H) ; ix) when R1 represents OH; R3 represents ethyl; R4 represents OH; R5 represents (H,methoxy) ; and R6 represents (R)-OH; then X does not represent (H,H) ; x) when R1 represents OH; R3 represents methyl, ethyl or allyl; R4 represents OH; R5 represents (H,OH) ; and R6 represents (R)-OH; then X does not represent O; and xi) when R1 represents OH; R3 represents allyl; R4 represents OH; R5 represents 0; and R6 represents
(R)-OH; then X does not represent O; and pharmaceutically acceptable derivatives thereof.
2. A compound of formula I, as claimed in claim l, wherein R1 represents H or OH.
3. A compound of formula I, as claimed in claim 1 or claim 2, wherein R4 represents H, OH, alkyl, halogen or amino.
4. A compound of formula I, as claimed in any one of the preceding claims, wherein R5 represents (H,OH) or (H,methoxy) .
5. A compound of formula I, as claimed in any one of the preceding claims, wherein R6 represents H, (R)-OH or Q amino•
6. A compound of formula I, as claimed in any one of the preceding claims, wherein R8 represents an amide of a C02H group or alkyl substituted by alkoxy.
7. A compound of formula I, as claimed in claim 1, which
5 is:
17-allyl-l,14-dihydroxy-l2-[2-(3-methoxycyclohexyl)-1- methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-ll,28- dioxa-4-azatricyclo[22.3.1.04'9]octacos-18-ene-2,3,10,16- tetraone ;
17-allyl-l,14-dihydroxy-12-[2-(cyclopentyl-3-carboxylic acid morpholine amide)-1-methylvinyl]-23,25-dimethoxy- 13,19,21,27-tetramethyl-ll,28-dioxa-4-azatricyclo [22.3.1.04•*9]octacos-18-ene-2,3,10,16-tetraone;
17-allyl-14-hydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-1- methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-ll,28- dioxa-4-azatricyclo[22.3.1.04'9]octacos-18-ene-2,3,10,16- tetraone; 17-allyl-14-hydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-1- methylvinyl]-23,25-dimethoxy-l,13,19,21,27-pentamethyl- 11,28-dioxa-4-azatricyclo[22.3.1.04'9]octacos-18-ene- 2,3,10,16-tetraone; 17-allyl-l-amino-14-hydroxy-12-[2-(4-hydroxy-3-methoxycyclo hexyl)-1-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetra methyl-11,28-dioxa-4-azatricyclo[22.3.1.04 * 9]octacos-18- ene-2,3,10,16-tetraone;
17-allyl-l-fluoro-14-hydroxy-12-[2-(4-hydroxy-3-methoxycyclo hexyl)-1-methylvinyl]-23,25-dimethoxy-13,19,21,27- tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.04,τ9]octacos- 18-ene-2,3,10,16-tetraone;
17-Allyl-l,14-dihydroxy-12-[2-(cyclopentyl-3-methanol(methyl ether) )-1-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetra methyl-11,28-dioxa-4-azatricyclo[22.3.1.0 '9]octacos-18- ene-2,3,10,16-tetraone; or
17-Allyl-l,14-dihydroxy-12-[2-(4-amino-3-methoxycyclohexyl)- 1-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl- ll,28-dioxa-4-azatricyclo[22.3.1.04 *9]octacos-18-ene- 2,3,10,16-tetraone.
8. The use of a compound of formula I, as defined in claim 1, as a pharmaceutical.
9. A pharmaceutical composition comprising a compound of formula I, as defined in claim 1, in association with a pharmaceutically acceptable adjuvant, diluent or carrier.
10. The use of a compound of formula I, as defined in claim 1, in the manufacture of a medicament for use as an immunosuppressive agent.
11. A method of effecting immunosuppression which comprises administering a therapeutically effective amount of a compound of formula I, as defined in claim 1, to a patient.
12. A process for the production of a compound of formula I as defined in claim 1, which comprises:
(a) producing a compound of formula I in which R1 and R2 together represent a second carbon-carbon bond between the carbon atoms to which they are attached, by dehydration of a corresponding compound in which R1 represents OH and R2 represents H;
(b) producing a compound of formula I in which R1 and R2 each represent hydrogen, by reduction of a corresponding compound in which R1 and R2 together represent a second carbon-carbon bond between the carbon atoms to which they are attached;
(c) producing a compound of formula I in which X represents (H,0H) , by reduction of a corresponding compound in which X represents 0; (d) producing a compound of formula I in which X represents (H,H) , by reduction of a corresponding compound in which X represents 0;
(e) producing a compound of formula I in which X represents 0, by oxidation of a corresponding compound in which X represents (H,0H) ;
(f) producing a compound of formula I in which R4 represents alkoxy, by reaction of a corresponding compound in which R4 represents OH and X represents (H,0H) with an alkanol;
(g) producing a compound of formula I in which R4 represents halogen, by reaction of a corresponding compound in which R4 represents OH with a suitable halogenating agent; (h) producing a compound of formula I in which R4 represents H or alkyl, by reaction of a corresponding compound in which R4 represents halogen with an organometallic reagent; (i) producing a compound of formula I in which R4 represents amino, by reaction of a corresponding compound in which R4 represents halogen with ammonia; (j) producing a compound of formula I in which X represents =NH, by reaction of a corresponding compound in which R4 represents halogen with ammonia; (k) producing a compound of formula I in which R4 represents S-alkyl, by reaction of a corresponding compound in which R4 represents halogen with an alkylthiol; (1) producing a compound of formula I in which R4 represents NHCHO, by reaction of a corresponding compound in which R4 represents amino with formic acid; ( ) producing a compound of formula I in which R4 represents NHCO-alkyl, by reaction of a corresponding compound in which R4 represents amino with an alkanoic anhydride;
(n) producing a compound of formula I in which R6 represents (S)-OH, by elimination of a leaving group from a correpsonding compound in which R6 represents the leaving group;
(o) producing a compound of formula I in which R6 represents H and R5 represents 0, by elimination of a leaving group from a correpsonding compound in which R6 represents the leaving group; (P) producing a compound of formula I in which R6 and R' together represent a second bond between the carbon atoms to which they are attached, by elimination of a leaving group from a correpsonding compound in which R6 represents the leaving group; (•3) producing a compound of formula I in which Y represents a cyclic group of formula III and R8 represents CHO, by elimination of a leaving group from a correpsonding compound in which R6 represents the leaving group; (r) producing a compound of formula I in which R6 represents halogen, by reaction of a corresponding compound in which R6 represents a leaving group with halide ion; (s) producing a compound of formula I in which R5 and R6 together represent a second bond between the carbon atoms to which they are attaches!. by elimination of halogen and alkoxy from a corresponding compound in which R5 represents alkoxy and R6 represents halogen; (t) producing a compound of formula I in which R5 represents (H,H) and R6 represents H, by reduction of a corresponding compound in which R5 and R6 together represent a second bond between the carbon atoms to which they are attached; (u) producing a compound of formula I in which R6 represents H, by the action of hydride on a corresponding compound in which R represents a leaving group; (v) producing a compound of formula I in which R6 represents -amino, by reduction of a corresponding compound in which R6 represents azido;
(w) producing a compound of formula I in which R6 represents alkylamino or alkanoylamino, by reaction of a corresponding compound in which R6 represents amino with a suitable alkylating or acylating reagent; (x) producing a compound of formula I in which R8 represents alkyl substituted by OH, by reduction of a corresponding compound in which R8 represents alkyl substituted by =0; (y) producing a compound of formula I in which R8 includes a carboxylic acid group, by oxidation of a corresponding compound in which R8 includes an aldehyde group; or (z) producing a compound of formula I in which R8 represents optionally substituted alkenyl, by a wittig reaction between a corresponding compound in which R8 includes an aldehyde and an appropriate Wittig reagent.
PCT/GB1991/000393 1990-03-13 1991-03-13 Immunosuppressive macrocyclic compounds WO1991013889A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
GB9005672A GB9005672D0 (en) 1990-03-13 1990-03-13 Compounds
GB9005672.2 1990-03-13
GB9008507A GB9008507D0 (en) 1990-04-17 1990-04-17 Compounds
GB9008556.4 1990-04-17
GB9008556A GB9008556D0 (en) 1990-04-17 1990-04-17 Compounds
GB9008507.7 1990-04-17
GB9009480A GB9009480D0 (en) 1990-04-27 1990-04-27 Compounds
GB9009480.6 1990-04-27
GB9017447.5 1990-08-09
GB9017447A GB9017447D0 (en) 1990-08-09 1990-08-09 Compounds
GB9023242.2 1990-10-25
GB9023242A GB9023242D0 (en) 1990-10-25 1990-10-25 Compounds

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19910905827 EP0594600A1 (en) 1990-03-13 1991-03-13 Immunosuppressive macrocyclic compounds
JP50581891A JPH05505798A (en) 1990-03-13 1991-03-13
US07924067 US5296489A (en) 1990-03-13 1991-03-13 Immunosuppressive macrocyclic compounds

Publications (1)

Publication Number Publication Date
WO1991013889A1 true true WO1991013889A1 (en) 1991-09-19

Family

ID=27547078

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1991/000393 WO1991013889A1 (en) 1990-03-13 1991-03-13 Immunosuppressive macrocyclic compounds

Country Status (3)

Country Link
EP (1) EP0594600A1 (en)
JP (1) JPH05505798A (en)
WO (1) WO1991013889A1 (en)

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143918A (en) * 1990-10-11 1992-09-01 Merck & Co., Inc. Halomacrolides and derivatives having immunosuppressive activity
US5162334A (en) * 1991-05-13 1992-11-10 Merck & Co., Inc. Amino O-alkyl, O-alkenyl and O-alkynlmacrolides having immunosuppressive activity
WO1992020688A1 (en) * 1991-05-13 1992-11-26 Merck & Co., Inc. Amino o-aryl, o-alkyl, o-alkenyl and o-alkynyl macrolides
US5189042A (en) * 1991-08-22 1993-02-23 Merck & Co. Inc. Fluoromacrolides having immunosuppressive activity
US5208228A (en) * 1989-11-13 1993-05-04 Merck & Co., Inc. Aminomacrolides and derivatives having immunosuppressive activity
US5208241A (en) * 1991-09-09 1993-05-04 Merck & Co., Inc. N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
WO1993011130A1 (en) * 1991-12-03 1993-06-10 Smithkline Beecham Plc Rapamycin derivative and its medicinal use
US5250678A (en) * 1991-05-13 1993-10-05 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
US5258389A (en) * 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5284877A (en) * 1992-06-12 1994-02-08 Merck & Co., Inc. Alkyl and alkenyl macrolides having immunosuppressive activity
US5284840A (en) * 1992-06-12 1994-02-08 Merck & Co., Inc. Alkylidene macrolides having immunosuppressive activity
US5310903A (en) * 1993-03-05 1994-05-10 Merck & Co., Inc. Imidazolidyl rapamycin derivatives
US5310901A (en) * 1993-03-05 1994-05-10 Merck & Co., Inc. O-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynlheteroarylrapamycin derivatives
EP0642516A4 (en) * 1991-09-05 1994-06-15 Abbott Lab Macrocyclic immunomodulators.
WO1995004061A1 (en) * 1993-07-30 1995-02-09 Abbott Laboratories Activated macrolactams having immunomodulatory activities
WO1995015328A1 (en) * 1993-11-30 1995-06-08 Abbott Laboratories Macrocyclic immunomodulators with novel cyclohexyl ring replacements
US5493019A (en) * 1993-05-27 1996-02-20 Sandoz Ltd. Tetrahydropyran derivatives
US5532248A (en) * 1991-05-13 1996-07-02 Merck Co., Inc. O-aryl,O-alkyl, and O-alkenyl-macrolides having immunosuppressive activity
US5599927A (en) * 1993-11-30 1997-02-04 Abbott Laboratories Macrocyclic immunomodulators with novel cyclohexyl ring replacements
EP0766685A1 (en) * 1994-06-15 1997-04-09 Merck &amp; Co., Inc. Aryl, alkyl, alkenyl, and alkynylmacrolides
US5686424A (en) * 1992-04-08 1997-11-11 Miles Inc. 2-oxoethyl derivatives as immunosuppressants
US5693648A (en) * 1994-09-30 1997-12-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides having immunosuppressive activity
US5708002A (en) * 1991-09-05 1998-01-13 Abbott Laboratories Macrocyclic immunomodulators
WO1999001458A1 (en) * 1997-06-30 1999-01-14 Novartis Ag Crystalline macrolides and process for their preparation
US6187757B1 (en) 1995-06-07 2001-02-13 Ariad Pharmaceuticals, Inc. Regulation of biological events using novel compounds
US6872383B2 (en) 1999-04-30 2005-03-29 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
US7067526B1 (en) 1999-08-24 2006-06-27 Ariad Gene Therapeutics, Inc. 28-epirapalogs
US7196192B2 (en) 1999-08-24 2007-03-27 Ariad Gene Therapeutics, Inc. 28-epirapalogs
EP2198858A1 (en) 1998-03-26 2010-06-23 Astellas Pharma Inc. Sustained release preparation of a macrolide compound like tacrolimus
EP2583678A2 (en) 2004-06-24 2013-04-24 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
US9402802B2 (en) 1998-12-03 2016-08-02 Meda Pharma Sarl Topical compositions comprising ascomycins
CN106074367A (en) * 2016-07-20 2016-11-09 中山大学中山眼科中心 FK506 compound/FKBP protein dimer containing pharmaceutical composition and preparation method thereof
WO2017156071A1 (en) * 2016-03-09 2017-09-14 Blade Therapeutics, Inc. Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0184162A2 (en) * 1984-12-03 1986-06-11 Fujisawa Pharmaceutical Co., Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
EP0323042A1 (en) * 1987-12-09 1989-07-05 FISONS plc Process to macrocyclic compounds
EP0356399A2 (en) * 1988-08-26 1990-02-28 Sandoz Ag Substituted 4-azatricyclo (22.3.1.04.9) octacos-18-ene derivatives, their preparation and pharmaceutical compositions containing them

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0184162A2 (en) * 1984-12-03 1986-06-11 Fujisawa Pharmaceutical Co., Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
EP0323042A1 (en) * 1987-12-09 1989-07-05 FISONS plc Process to macrocyclic compounds
EP0356399A2 (en) * 1988-08-26 1990-02-28 Sandoz Ag Substituted 4-azatricyclo (22.3.1.04.9) octacos-18-ene derivatives, their preparation and pharmaceutical compositions containing them

Cited By (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208228A (en) * 1989-11-13 1993-05-04 Merck & Co., Inc. Aminomacrolides and derivatives having immunosuppressive activity
US5143918A (en) * 1990-10-11 1992-09-01 Merck & Co., Inc. Halomacrolides and derivatives having immunosuppressive activity
US5162334A (en) * 1991-05-13 1992-11-10 Merck & Co., Inc. Amino O-alkyl, O-alkenyl and O-alkynlmacrolides having immunosuppressive activity
WO1992020688A1 (en) * 1991-05-13 1992-11-26 Merck & Co., Inc. Amino o-aryl, o-alkyl, o-alkenyl and o-alkynyl macrolides
US5532248A (en) * 1991-05-13 1996-07-02 Merck Co., Inc. O-aryl,O-alkyl, and O-alkenyl-macrolides having immunosuppressive activity
US5250678A (en) * 1991-05-13 1993-10-05 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
US5189042A (en) * 1991-08-22 1993-02-23 Merck & Co. Inc. Fluoromacrolides having immunosuppressive activity
EP0642516A4 (en) * 1991-09-05 1994-06-15 Abbott Lab Macrocyclic immunomodulators.
US5708002A (en) * 1991-09-05 1998-01-13 Abbott Laboratories Macrocyclic immunomodulators
EP0642516A1 (en) * 1991-09-05 1995-03-15 Abbott Laboratories Macrocyclic immunomodulators
US5208241A (en) * 1991-09-09 1993-05-04 Merck & Co., Inc. N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
WO1993011130A1 (en) * 1991-12-03 1993-06-10 Smithkline Beecham Plc Rapamycin derivative and its medicinal use
US5491229A (en) * 1991-12-03 1996-02-13 Smithkline Beecham Plc Rapamycin derivative
US5686424A (en) * 1992-04-08 1997-11-11 Miles Inc. 2-oxoethyl derivatives as immunosuppressants
US5284877A (en) * 1992-06-12 1994-02-08 Merck & Co., Inc. Alkyl and alkenyl macrolides having immunosuppressive activity
US5284840A (en) * 1992-06-12 1994-02-08 Merck & Co., Inc. Alkylidene macrolides having immunosuppressive activity
US5258389A (en) * 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5310903A (en) * 1993-03-05 1994-05-10 Merck & Co., Inc. Imidazolidyl rapamycin derivatives
US5310901A (en) * 1993-03-05 1994-05-10 Merck & Co., Inc. O-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynlheteroarylrapamycin derivatives
US5493019A (en) * 1993-05-27 1996-02-20 Sandoz Ltd. Tetrahydropyran derivatives
US5508397A (en) * 1993-07-30 1996-04-16 Abbott Laboratories Activated macrolactams
WO1995004061A1 (en) * 1993-07-30 1995-02-09 Abbott Laboratories Activated macrolactams having immunomodulatory activities
US5599927A (en) * 1993-11-30 1997-02-04 Abbott Laboratories Macrocyclic immunomodulators with novel cyclohexyl ring replacements
US5612350A (en) * 1993-11-30 1997-03-18 Abbott Laboratories Macrocyclic immunomodulators with novel cyclohexyl ring replacements
WO1995015328A1 (en) * 1993-11-30 1995-06-08 Abbott Laboratories Macrocyclic immunomodulators with novel cyclohexyl ring replacements
EP0766685A4 (en) * 1994-06-15 1997-07-16 Merck & Co Inc Aryl, alkyl, alkenyl, and alkynylmacrolides
EP0766685A1 (en) * 1994-06-15 1997-04-09 Merck &amp; Co., Inc. Aryl, alkyl, alkenyl, and alkynylmacrolides
US5880280A (en) * 1994-06-15 1999-03-09 Merck & Co., Inc. Aryl, alkyl, alkenyl and alkynylmacrolides having immunosuppressive activity
US5693648A (en) * 1994-09-30 1997-12-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides having immunosuppressive activity
US6649595B2 (en) 1995-06-07 2003-11-18 Ariad Gene Therapeutics, Inc. Regulation of biological events using novel compounds
US6187757B1 (en) 1995-06-07 2001-02-13 Ariad Pharmaceuticals, Inc. Regulation of biological events using novel compounds
JP2006151999A (en) * 1997-06-30 2006-06-15 Novartis Ag Crystalline macrolide and process for preparation thereof
US6423722B1 (en) 1997-06-30 2002-07-23 Novartis Ag Crystalline macrolides and process for their preparation
JP4504323B2 (en) * 1997-06-30 2010-07-14 ノバルティス アーゲー Crystalline macrolides and process for their preparation
WO1999001458A1 (en) * 1997-06-30 1999-01-14 Novartis Ag Crystalline macrolides and process for their preparation
EP2198858A1 (en) 1998-03-26 2010-06-23 Astellas Pharma Inc. Sustained release preparation of a macrolide compound like tacrolimus
US9402802B2 (en) 1998-12-03 2016-08-02 Meda Pharma Sarl Topical compositions comprising ascomycins
US6872383B2 (en) 1999-04-30 2005-03-29 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
US7063857B1 (en) 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
US7067526B1 (en) 1999-08-24 2006-06-27 Ariad Gene Therapeutics, Inc. 28-epirapalogs
US7196192B2 (en) 1999-08-24 2007-03-27 Ariad Gene Therapeutics, Inc. 28-epirapalogs
EP2583678A2 (en) 2004-06-24 2013-04-24 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
WO2017156071A1 (en) * 2016-03-09 2017-09-14 Blade Therapeutics, Inc. Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof
CN106074367A (en) * 2016-07-20 2016-11-09 中山大学中山眼科中心 FK506 compound/FKBP protein dimer containing pharmaceutical composition and preparation method thereof

Also Published As

Publication number Publication date Type
JPH05505798A (en) 1993-08-26 application
EP0594600A1 (en) 1994-05-04 application

Similar Documents

Publication Publication Date Title
US4031098A (en) Camptothecin analogues
US6015815A (en) Tetrazole-containing rapamycin analogs with shortened half-lives
USRE39151E1 (en) Process for the preparation and purification of thiol-containing maytansinoids
US5143918A (en) Halomacrolides and derivatives having immunosuppressive activity
US5023262A (en) Hydrogenated rapamycin derivatives
US5023264A (en) Rapamycin oximes
US5250678A (en) O-aryl, O-alkyl, O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
US5583139A (en) Marcolide immunomodulators
US5102876A (en) Reduction products of rapamycin
US5169851A (en) Rapamycin analog as immunosuppressants and antifungals
US5362718A (en) Rapamycin hydroxyesters
US5162333A (en) Aminodiesters of rapamycin
US5138051A (en) Rapamycin analogs as immunosuppressants and antifungals
US5387680A (en) C-22 ring stabilized rapamycin derivatives
US5955457A (en) Water soluble rapamycin esters
US5391730A (en) Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5164399A (en) Rapamycin pyrazoles
US5441977A (en) 21-norrapamycin
US5985890A (en) Rapamycin derivatives
US5208228A (en) Aminomacrolides and derivatives having immunosuppressive activity
US5202332A (en) Rapamycin analog as immunosuppressant
US5489680A (en) Carbamates of rapamycin
US6605595B1 (en) Avermectin derivatives
US5525610A (en) 42-Epi-rapamycin and pharmaceutical compositions thereof
US5665772A (en) O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1991905827

Country of ref document: EP

NENP Non-entry into the national phase in:

Ref country code: CA

WWP Wipo information: published in national office

Ref document number: 1991905827

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1991905827

Country of ref document: EP